Zoetis (ZTS) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 28, 2014	Nov. 07, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	28-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ZTS	'
Entity Registrant Name	'Zoetis Inc.	'
Entity Central Index Key	'0001555280	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	501,324,843

CONDENSED_CONSOLIDATED_AND_COM

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF INCOME(UNAUDITED) (USD $)	3 Months Ended				9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013
Income Statement [Abstract]	'		'		'		'
Revenue	$1,210	[1]	$1,103	[1]	$3,465	[1]	$3,307	[1]
Costs and expenses:	'		'		'		'
Cost of sales(a)	434	[2]	385	[2]	1,226	[2]	1,203	[2]
Selling, general and administrative expenses(a)	394	[2]	399	[2]	1,146	[2]	1,155	[2]
Research and development expenses(a)	93	[2]	93	[2]	272	[2]	278	[2]
Amortization of intangible assets(a)	16	[2]	15	[2]	46	[2]	45	[2]
Restructuring charges and certain acquisition-related costs	2		3		10		-10
Interest expense, net of capitalized interest	29		29		87		83
Other (income)/deductions—net	4		-6		13		-11
Income before provision for taxes on income	238	[3]	185	[3]	665	[3]	564	[3]
Provision for taxes on income	71		54		204		165
Net income before allocation to noncontrolling interests	167		131		461		399
Less: Net income attributable to noncontrolling interests	1		0		4		0
Net income attributable to Zoetis Inc.	$166		$131		$457		$399
Earnings per share attributable to Zoetis Inc. stockholders:	'		'		'		'
Basic (in dollars per share)	$0.33		$0.26		$0.91		$0.80
Diluted (in dollars per share)	$0.33		$0.26		$0.91		$0.80
Weighted-average common shares outstanding:	'		'		'		'
Basic (in shares)	501,453		500,000		500,887		500,000
Diluted (in shares)	502,445		500,354		501,610		500,227
Dividends paid per common share (in dollars per share)	$0.07		$0.07		$0.14		$0.20
[1]	Revenue denominated in euros was $175 million and $525 million for the three and nine months ended September 28, 2014, respectively, and $159 million and $493 million for the three and nine months ended September 29, 2013, respectively.
[2]	Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as these intangible assets benefit multiple business functions. Amortization expense related to finite-lived acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate, in the condensed consolidated statements of income.
[3]	Defined as income before provision for taxes on income.

CONDENSED_CONSOLIDATED_AND_COM1

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013
Statement of Comprehensive Income [Abstract]	'		'		'		'
Net income before allocation to noncontrolling interests	$167		$131		$461		$399
Other comprehensive income/(loss), net of taxes and reclassification adjustments:	'		'		'		'
Foreign currency translation adjustments, net	-38		-62		-20		-79
Benefit plans: Actuarial losses, net(a)	-1	[1]	0	[1]	-1	[1]	-3	[1]
Plan settlement, net(b)	0	[2]	0	[2]	3	[2]	0	[2]
Total other comprehensive loss, net of tax	-39		-62		-18		-82
Comprehensive income before allocation to noncontrolling interests	128		69		443		317
Less: Comprehensive income attributable to noncontrolling interests	2		0		4		0
Comprehensive income attributable to Zoetis Inc.	$126		$69		$439		$317
[1]	Presented net of reclassification adjustments and tax impacts, which are not significant in any period presented. Reclassification adjustments related to benefit plans are generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, general and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income.
[2]	Reflects the first quarter 2014 settlement charge associated with the 2012 sale of our Netherlands manufacturing facility which was recorded to Other (income)/deductions—net. See Note 12. Benefit Plans for additional information.

CONDENSED_CONSOLIDATED_AND_COM2

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (UNAUDITED) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Assets	'	'
Cash and cash equivalents	$598	$610
Accounts receivable, less allowance for doubtful accounts of $31 in 2014 and $31 in 2013	1,057	1,138
Inventories	1,388	1,293
Current deferred tax assets	106	97
Other current assets	204	219
Total current assets	3,353	3,357
Property, plant and equipment, less accumulated depreciation of $1,143 in 2014 and $1,028 in 2013	1,313	1,295
Goodwill	982	982
Identifiable intangible assets, less accumulated amortization	757	803
Noncurrent deferred tax assets	55	63
Other noncurrent assets	67	58
Total assets	6,527	6,558
Liabilities and Equity	'	'
Short-term borrowings	10	15
Accounts payable	259	506
Accrued compensation and related items	201	229
Income taxes payable	86	40
Dividends payable	0	36
Other Liabilities, Current	442	589
Total current liabilities	998	1,415
Long-term debt	3,642	3,642
Noncurrent deferred tax liabilities	265	322
Other taxes payable	57	49
Other noncurrent liabilities	176	168
Total liabilities	5,138	5,596
Commitments and contingencies	'	'
Preferred stock, $0.01 par value: 1,000,000,000 authorized, none issued	0	0
Common stock, $0.01 par value: 6,000,000,000 authorized; 501,209,488 and 500,007,735 shares issued; 501,195,696 and 500,007,428 shares outstanding at September 28, 2014, and December 31, 2013, respectively	5	5
Treasury stock, at cost, 13,792 and 307 shares of common stock at September 28, 2014, and December 31, 2013, respectively	0	0
Additional paid-in capital	938	878
Retained earnings	661	276
Accumulated other comprehensive loss	-240	-219
Total Zoetis Inc. equity	1,364	940
Equity attributable to noncontrolling interests	25	22
Total equity	1,389	962
Total liabilities and equity	$6,527	$6,558

CONDENSED_CONSOLIDATED_AND_COM3

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (UNAUDITED) (PARENTHETICAL) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, except Share data, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Allowance for doubtful accounts	$31	$31
Accumulated depreciation	$1,143	$1,028
Common stock, par value (in dollars per share)	$0.01	$0.01
Preferred Stock, Par or Stated Value Per Share	$0.01	$0.01
Common Stock, Shares Authorized	6,000,000,000	6,000,000,000
Common stock, shares issued	501,209,488	500,007,735
Common stock, shares outstanding	501,195,696	500,007,428
Preferred Stock, Shares Authorized	1,000,000,000	1,000,000,000,000,000
Treasury Stock, Shares	13,792	307
Preferred Stock, Shares Issued	0	0

CONDENSED_CONSOLIDATED_AND_COM4

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY(UNAUDITED) CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY(UNAUDITED) (USD $)		Total	Common Stock		Business Unit Equity		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comp. Income/(Loss)		Equity Attributable to Noncontrolling Interests
In Millions, unless otherwise specified
Beginning balance at Dec. 31, 2012		$4,041	$0	[1]	$4,183	[2]	$0	$0	($157)		$15
Increase (Decrease) in Stockholders' Equity [Roll Forward]		'	'		'		'	'	'		'
Net income		399	'		94	[2]	'	305	'		0
Other comprehensive income (loss), net of tax		-82	'		'		'	'	-82		'
Share-based compensation awards(c)	[3]	37	'		3	[2]	34	'	'		'
Net transfers - Pfizer		-271	'		-271	[2]	'	'	'		'
Separation adjustments	[4]	450	'	[1]	414	[2]	34	'	-6		8
Employee benefit plan contribution from Pfizer Inc.	[5]	1	'		'		1	'	'		'
Reclassification of net liability due to Pfizer, Inc.	[6]	-60	'	[1]	-60	[2]	'	'	'		'
Consideration paid to Pfizer Inc. in connection with the Separation	[7]	-3,551	'		'		-3,551	'	'		'
Issuance of common stock to Pfizer Inc. in connection with the Separation and reclassification of Business Unit Equity	[7]	0	5	[1]	-4,363	[2]	4,358	'	'		'
Dividends declared		-98	'		'		'	-98	'		'
Ending balance at Sep. 29, 2013		866	5	[1]	0	[2]	876	207	-245		23
Beginning balance at Dec. 31, 2013		962	5	[1]	0	[2]	878	276	-219		22
Increase (Decrease) in Stockholders' Equity [Roll Forward]		'	'		'		'	'	'		'
Net income		461	'		'		'	457	'		4
Other comprehensive income (loss), net of tax		-18	'		'		'	'	-18		0
Share-based compensation awards(c)	[3]	23	'		'		23	'	'		'
Stock Issued During Period, Value, Employee Benefit Plan	[8]	32	'	[1]	'	[2]	32	'	'		'
Employee benefit plan contribution from Pfizer Inc.	[5]	2	'	[1]	'	[2]	2	'	'		'
Dividends declared		-73	'		'		'	-72	'		-1
Pension plan transfer from Pfizer Inc.	[9]	0	'	[1]	'	[2]	3	'	-3	[10]	'
Ending balance at Sep. 28, 2014		$1,389	$5	[1]	$0	[2]	$938	$661	($240)		$25
[1]	As of SeptemberB 28, 2014, there were 501,195,696 outstanding shares of common stock and 13,792 shares of treasury stock. Treasury stock is recognized at the cost to reacquire the shares, which totaled $0.4 million for the nine months ended September 28, 2014.
[2]	All amounts associated with Business Unit Equity relate to periods prior to the Separation. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
[3]	The nine months ended September 28, 2014 includes the issuance of 100,072 shares of Zoetis Inc. common stock and an increase of 13,485 shares of treasury stock associated with exercises of employee share-based awards. The nine months ended September 29, 2013 includes the issuance of 7,080 shares of Zoetis Inc. common stock and the reacquisition of 247 treasury shares. Treasury shares are reacquired from employees for withholding tax purposes in connection with the vesting and exercise of awards under our equity compensation plan. For additional information regarding share-based compensation, see Note 13. Share-Based Payments.
[4]	For additional information, see Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
[5]	Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans. See Note 12. Benefit Plans.
[6]	Represents the reclassification of the Receivable from Pfizer Inc. and the Payable to Pfizer Inc. from Business Unit Equity as of the Separation date. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
[7]	Reflects the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
[8]	Reflects company matching and profit-sharing contributions funded through the issuance of 1,101,681 shares of Zoetis Inc. common stock.
[9]	Reflects the 2014 transfers of defined benefit pension plans from Pfizer Inc. and the associated reclassification from Additional Paid in Capital to Accumulated Other Comprehensive Loss. See Note 12. Benefit Plans.
[10]	Reflects the 2014 transfers of defined benefit pension plans from Pfizer Inc. and the associated reclassification from Additional Paid in Capital to Accumulated other Comprehensive Loss. See Note 12 Benefit Plans.

CONDENSED_CONSOLIDATED_AND_COM5

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY(UNAUDITED) (PARENTHETICAL) (USD $)	9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013
Treasury Stock, Value, Acquired, Cost Method	$0.40	'
Common Stock, Shares, Outstanding	501,195,696	'
Treasury Stock, Shares	13,792	'
Stock Issued During Period, Shares, New Issues	100,072	7,080
Treasury Stock, Shares, Acquired	13,485	247
Other Postretirement Benefit Plan, Defined Benefit [Member]	'	'
Stock Issued During Period, Shares, New Issues	1,101,681	'

CONDENSED_CONSOLIDATED_AND_COM6

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013
Operating Activities	'		'
Net income before allocation to noncontrolling interests	$461		$399
Adjustments to reconcile net income before noncontrolling interests to net cash provided by/(used in) operating activities	'		'
Depreciation and amortization expense	151	[1]	151	[1]
Share-based compensation expense	22		37
Asset write-offs and asset impairments	8		4
Deferred taxes	-60		-47
Employee benefit plan contribution from Pfizer Inc.	2		1
Other non-cash adjustments	-8		0
Other changes in assets and liabilities, net of acquisitions and divestitures and transfers with Pfizer Inc.	-337		-162
Net cash provided by operating activities	239		383
Investing Activities	'		'
Purchases of property, plant and equipment	-129		-135
Milestone payment related to previously acquired intangibles	-15		0
Net proceeds from sales of assets	8		7
Other investing activities	-1		0
Net cash used in investing activities	-137		-128
Financing Activities	'		'
(Decrease)/increase in short-term borrowings, net	-5		11
Proceeds from issuance of long-term debtbsenior notes, net of discount and fees	0		2,625
Stock-based compensation-related proceeds and excess tax benefits	2		0
Consideration paid to Pfizer Inc. in connection with the Separation(a)	0	[2]	-2,559	[2]
Cash dividends paid	-109		-65
Other net financing activities with Pfizer Inc.	0		-184
Net cash used in financing activities	-112		-172
Effect of exchange-rate changes on cash and cash equivalents	-2		-11
Net (decrease)/increase in cash and cash equivalents	-12		72
Cash and cash equivalents at beginning of period	610		317
Cash and cash equivalents at end of period	598		389
Cash paid during the period for:	'		'
Income taxes	210		77
Interest, net of capitalized interest	117		60
Non-cash transactions:	'		'
Intangible asset acquisition(b)	8	[3]	0	[3]
Dividends declared, not paid	0		33
Zoetis Inc. senior notes transferred to Pfizer Inc. in connection with the Separation(b)	$0	[4]	$992	[4]
[1]	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
[2]	Reflects the Separation transaction. Amount is net of the non-cash portion. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.
[3]	Reflects the non-cash portion of the acquisition of product registration and application rights from Pfizer in the third quarter of 2014. See Note 17. Transactions and Agreements with Pfizer.
[4]	Reflects the non-cash portion of the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: The Separation.

Organization

Organization	9 Months Ended
	Sep. 28, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization	'
	Organization
	Zoetis Inc. (including its subsidiaries, collectively, Zoetis, the company, we, us or our) is a global leader in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. We organize and operate our business in four geographic regions: the United States (U.S.); Europe/Africa/Middle East (EuAfME); Canada/Latin America (CLAR); and Asia/Pacific (APAC).
	We directly market our products in approximately 70 countries across North America, Europe, Africa, Asia, Australia and South America, and our products are sold in more than 120 countries, including developed markets and emerging markets. Our revenue is mostly generated in the U.S. and EuAfME. We have a diversified business, marketing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals); and within five major product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Separation_Activities_and_Init

Separation Activities and Initial Public Offering	9 Months Ended
	Sep. 28, 2014
Separation Activities and Initial Public Offering [Abstract]	'
The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer	'
	The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer
	Pfizer Inc. (Pfizer) formed Zoetis to acquire, own and operate the animal health business of Pfizer. On June 24, 2013, Pfizer completed an exchange offer resulting in the full separation of Zoetis from Pfizer. For additional information, see E. Exchange Offer.
	A.	The Separation
	In the first quarter of 2013, through a series of steps (collectively, the Separation), Pfizer transferred to us its subsidiaries holding substantially all of the assets and liabilities of its animal health business. In exchange, we transferred to Pfizer: (i) all of the issued and outstanding shares of our Class A common stock; (ii) all of the issued and outstanding shares of our Class B common stock; (iii) $1.0 billion in senior notes (see C. Senior Notes Offering below); and (iv) an amount of cash equal to substantially all of the net proceeds received in the senior notes offering (approximately $2.5 billion).
	B.	Adjustments Associated with the Separation
	In connection with the Separation, certain animal health assets and liabilities included in the pre-Separation balance sheet were retained by Pfizer and certain non-animal health assets and liabilities (not included in the pre-Separation balance sheet) were transferred to Zoetis. The 2013 adjustments to the historical balance sheet of Zoetis (collectively, the Separation Adjustments) represented approximately $445 million of net liabilities retained by Pfizer.
	The Separation Adjustment associated with Accumulated Other Comprehensive Loss reflects the accumulated currency translation adjustment based on the actual legal entity structure of Zoetis.
	C.	Senior Notes Offering
	In connection with the Separation, on January 28, 2013, we issued $3.65 billion aggregate principal amount of our senior notes (the senior notes offering) in a private placement, with an original issue discount of $10 million. For additional information, see Note 9A. Financial Instruments: Debt.
	D.	Initial Public Offering (IPO)
	After the Separation, on February 6, 2013, an IPO of 99,015,000 shares of our Class A common stock (including the exercise of the underwriters' over-allotment option) at a price of $26.00 per share was completed. Pfizer retained the net proceeds from the IPO.
	Immediately following the IPO, there were 99,015,000 outstanding shares of Class A common stock and 400,985,000 outstanding shares of Class B common stock. The rights of the holders of Class A common stock and Class B common stock were identical, except with respect to voting and conversion rights. Following the IPO, Pfizer owned all of the outstanding shares of our Class B common stock, all of which was converted to Class A common stock in connection with the Exchange Offer. See E. Exchange Offer. There are no longer any shares of our Class B common stock outstanding.
	As of February 6, 2013, the total number of shares authorized to issue are 6,000,000,000 shares of common stock and 1,000,000,000 shares of preferred stock.
	In connection with the IPO, we entered into certain agreements that provide a framework for an ongoing relationship with Pfizer. For additional information, see Note 17. Transactions and Agreements with Pfizer.
	E.	Exchange Offer
	On May 22, 2013, Pfizer announced an exchange offer (the Exchange Offer) whereby Pfizer shareholders could exchange a portion of Pfizer common stock for Zoetis common stock. The Exchange Offer was completed on June 24, 2013, resulting in the full separation of Zoetis and the disposal of Pfizer's entire ownership and voting interest in Zoetis.

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 28, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements were prepared following the requirements of the Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted. Balance sheet amounts and operating results for subsidiaries operating outside the United States are as of and for the three and nine-month periods ended August 24, 2014, and August 25, 2013.
	Revenue, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
	We are responsible for the unaudited condensed consolidated financial statements included in this Form 10-Q. The condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our financial position and operating results. The information included in this interim report should be read in conjunction with the financial statements and accompanying notes included in our 2013 Annual Report on Form 10-K.
	Certain reclassifications of prior year information have been made to conform to the current year's presentation. In the first quarter of 2014, we realigned our segment reporting with respect to our Client Supply Services organization (CSS), which provides contract manufacturing services to third parties, to reflect how our chief operating decision maker currently evaluates our financial results. The revenue and earnings associated with CSS are now reported within Other business activities, separate from the four reportable segments. In 2013, CSS results were reported in the EuAfME segment. Such revisions have no impact on our consolidated financial condition, results of operations or cash flows for the periods presented. We have revised our segment results presented herein to reflect this new segment structure, including for the comparable 2013 period. For additional information, see Note 16. Segment and Other Revenue Information.
	A.	Basis of Presentation Prior to the Separation
	Prior to the Separation, the combined financial statements were derived from the consolidated financial statements and accounting records of Pfizer and included allocations for direct costs and indirect costs attributable to the operations of the animal health business of Pfizer. The pre-Separation financial statements and activities do not purport to reflect what the results of operations, comprehensive income/(loss), financial position, equity or cash flows would have been had we operated as an independent public company during the period presented.
	•	The pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013, includes allocations from certain support functions (Enabling Functions) that were provided on a centralized basis within Pfizer, such as expenses for business technology, facilities, legal, finance, human resources, and, to a lesser extent, business development, public affairs and procurement, among others, as Pfizer did not routinely allocate these costs to any of its business units. These allocations were based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods (e.g., using third-party sales, headcount, etc.), depending on the nature of the services.
	Costs associated with business technology, facilities and human resources were allocated primarily using proportional allocation methods and, for legal and finance, primarily using specific identification. In all cases, for support function costs where proportional allocation methods were used, we determined whether the costs are primarily influenced by headcount (such as a significant majority of facilities and human resources costs) or by the size of the business (such as most business technology costs), and we also determined whether the associated scope of those services provided were global, regional or local. Based on those analyses, the costs were allocated based on our share of worldwide revenue, domestic revenue, international revenue, regional revenue, country revenue, worldwide headcount, country headcount or site headcount, as appropriate.
	As a result, costs associated with business technology and legal that were not specifically identified were mostly allocated based on revenue drivers and, to a lesser extent, based on headcount drivers; costs associated with finance that were not specifically identified were all allocated based on revenue drivers; and costs associated with facilities and human resources that were not specifically identified were predominantly allocated based on headcount drivers.
	•	The pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013, includes allocations of certain manufacturing and supply costs incurred by manufacturing plants that were shared with other Pfizer business units, Pfizer’s global external supply group and Pfizer’s global logistics and support group (collectively, Pfizer Global Supply, or PGS). These costs may include manufacturing variances and changes in the standard costs of inventory, among others, as Pfizer did not routinely allocate these costs to any of its business units. These allocations were based on either a specific identification basis or, when specific identification is not practicable, proportional allocation methods, such as animal health identified manufacturing costs, depending on the nature of the costs.
	•	The pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013, also includes allocations from the Enabling Functions and PGS for restructuring charges, integration costs, additional depreciation associated with asset restructuring and implementation costs, as Pfizer did not routinely allocate these costs to any of its business units. For additional information about allocations of restructuring charges and other costs associated with acquisitions and cost-reduction/productivity initiatives, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
	•	The pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013, includes an allocation of share-based compensation expense and certain other compensation expense items, such as certain fringe benefit expenses, maintained on a centralized basis within Pfizer, as Pfizer does not routinely allocate these costs to any of its business units. For additional information about allocations of share-based payments, see Note 13. Share-Based Payments.
	The allocated expenses from Pfizer include the items noted below for the pre-Separation period for the nine months ended September 29, 2013.
	•	Enabling Functions operating expenses––approximately $11 million (in Selling, general and administrative expenses).
	•	Other costs associated with cost reduction/productivity initiatives—additional depreciation associated with asset restructuring—approximately $2 million (in Selling, general and administrative expenses).
	•	Other costs associated with cost reduction/productivity initiatives—implementation costs—approximately $1 million (in Selling, general and administrative expenses).
	•	Share-based compensation expense—approximately $3 million ($1 million in Cost of sales and $2 million in Selling, general and administrative expenses).
	•	Compensation-related expenses—approximately $1 million (in Selling, general and administrative expenses).
	•	Interest expense—approximately $2 million.
	Management believes that the allocations were a reasonable reflection of the services received or the costs incurred on behalf of Zoetis and its operations and that the pre-Separation period included in the condensed consolidated statement of income for the nine months ended September 29, 2013, reflects all of the costs of the animal health business of Pfizer.
	B.	Basis of Presentation After the Separation
	The unaudited condensed consolidated financial statements for the three and nine months ended September 29, 2013, comprise the following: (i) the results of operations, comprehensive income, and cash flow amounts for the period prior to the Separation (see above), which includes allocations for direct costs and indirect costs attributable to the operations of the animal health business; and (ii) the amounts for the period after the Separation, which reflect the results of operations, comprehensive income, financial position, equity and cash flows resulting from our operation as an independent public company.
	The income tax provision prepared after the Separation is based on the actual legal entity structure of Zoetis, with certain accommodations pursuant to a tax matters agreement. For additional information, see Note 17. Transactions and Agreements with Pfizer.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 28, 2014
Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	Significant Accounting Policies
	New Accounting Standards
	In May 2014, the Financial Accounting Standards Board (FASB) issued an accounting standards update that outlines a new, single comprehensive model for companies to use in accounting for revenue arising from contracts with customers. This update supersedes most current revenue recognition guidance under U.S. GAAP. The core principle of the new guidance is that an entity should recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance includes a five-step model for determining how, when and how much revenue should be recognized. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The provisions of the new standard are effective beginning January 1, 2017, for annual and interim reporting periods. Early adoption is not permitted. The new standard allows for either full retrospective or modified retrospective transition upon adoption. We are currently assessing the transition method we will elect for adoption as well as the potential impact that adopting this new guidance will have on our consolidated financial statements.
	In July 2013, the FASB issued an accounting standards update regarding the presentation of an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. Under this new standard, this unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset if available under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, the unrecognized tax benefit should be presented in the financial statements as a separate liability. The assessment is based on the unrecognized tax benefits and deferred tax assets that exist at the reporting date. The provisions of the new standard were effective January 1, 2014, for annual and interim reporting periods and did not have a significant impact on our consolidated financial statements.
	In March 2013, the FASB issued an accounting standards update regarding the accounting for cumulative translation adjustment (CTA) upon derecognition of assets or investment within a foreign entity. This new standard provides additional CTA accounting guidance on sales or transfers of foreign entity investments and assets as well as step acquisitions involving a foreign entity. The provisions of the new standard were effective as of January 1, 2014, and did not have a significant impact on our consolidated financial statements.
	In February 2013, the FASB issued an accounting standards update regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings. The provisions of this standard require that these obligations are measured at the amount representing the agreed upon obligation of the company as well as additional liability amounts it expects to assume on behalf of other parties in the arrangement. The provisions of the new standard were effective January 1, 2014, and did not have a significant impact on our consolidated financial statements.

Restructuring_Charges_and_Othe

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	9 Months Ended
	Sep. 28, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	'
	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
	During the nine months ended September 28, 2014, we recorded a restructuring charge of $6 million related to employee severance costs in EuAfME as a result of an initiative to reduce costs and better align our organizational structure.
	In the fourth quarter of 2012, when we were a business unit of Pfizer, we announced a restructuring plan related to our operations in Europe. In connection with these actions, we recorded a pre-tax charge of $27 million to recognize employee termination costs. As a result of becoming a standalone public company (no longer being a majority owned subsidiary of Pfizer) and related economic consideration, we revisited this restructuring action and decided to no longer implement this restructuring plan. As such, we reversed the existing reserve of $27 million in the second quarter of 2013.
	We incurred significant costs in connection with Pfizer’s cost-reduction initiatives (several programs initiated since 2005), and the acquisitions of Fort Dodge Animal Health (FDAH) on October 15, 2009, and King Animal Health (KAH) on January 31, 2011.
	For example:
	•	in connection with the cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems; and
	•	in connection with our acquisition activity, we typically incur costs and charges associated with executing the transactions, integrating the acquired operations, which may include expenditures for consulting and the integration of systems and processes, product transfers and restructuring the consolidated company, which may include charges related to employees, assets and activities that will not continue in the consolidated company.
	All operating functions can be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as functions such as business technology, shared services and corporate operations.
	The components of costs incurred in connection with restructuring initiatives, acquisitions and cost-reduction/productivity initiatives follow:
			Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
	(MILLIONS OF DOLLARS)		2014			2013			2014			2013
	Restructuring charges and certain acquisition-related costs:
	Integration costs(a)		$	1		$	3		$	5		$	16
	Restructuring charges(b):
	Employee termination costs		1			—			4			(26		)
	Accelerated depreciation		—			—			1			—
	Total Restructuring charges and certain acquisition-related costs		2			3			10			(10		)
	Other costs associated with cost-reduction/productivity initiatives:
	Additional depreciation associated with asset restructuring––direct(c)		—			—			—			1
	Additional depreciation associated with asset restructuring––allocated(c)		—			—			—			2
	Implementation costs––allocated(d)		—			—			—			1
	Total costs associated with acquisitions and cost-reduction/productivity initiatives		$	2		$	3		$	10		$	(6	)
	(a)	Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.
	(b)	The restructuring charges for the three and nine months ended September 28, 2014, include employee severance costs in EuAfME ($1 million and $6 million, respectively). Additionally, the nine months ended September 28, 2014, includes a reversal of a previously established reserve as a result of a change in estimate of severance costs ($2 million benefit), and accelerated depreciation related to the exiting of a research facility ($1 million). The restructuring benefit for the nine months ended September 29, 2013, is primarily related to the reversal of certain employee termination expenses associated with our operations in Europe.
	The restructuring charges/benefits are associated with the following:
	•	For the three months ended September 28, 2014––EuAfME ($1 million).
	•	For the nine months ended September 28, 2014––EuAfME ($6 million) and Manufacturing/research/corporate ($1 million benefit).
	•	For the nine months ended September 29, 2013––Manufacturing/research/corporate ($26 million benefit).
	(c)	Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended September 29, 2013, included in Cost of Sales ($1 million) and Selling, general and administrative expenses ($2 million).
	(d)	Implementation costs—allocated represent external, incremental costs directly related to implementing cost reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.
	The components of and changes in our restructuring accruals follow:
			Employee
			Termination			Accelerated			Exit
	(MILLIONS OF DOLLARS)		Costs			Depreciation			Costs			Accrual
	Balance, December 31, 2013(a)		$	15		$	—		$	6		$	21
	Provision		4			1			—			5
	Utilization and other(b)		(7		)	(1		)	(3		)	(11		)
	Balance, September 28, 2014(a)		$	12		$	—		$	3		$	15
	(a)	At September 28, 2014, and December 31, 2013, included in Other current liabilities ($7 million and $13 million, respectively) and Other noncurrent liabilities ($7 million and $8 million, respectively).
	(b)	Includes adjustments for foreign currency translation.

Other_IncomeDeductions_Net

Other (Income)/Deductions - Net	9 Months Ended
	Sep. 28, 2014
Other Income and Expenses [Abstract]	'
Other (Income)/Deductions - Net	'
	Other (Income)/Deductions—Net
	The components of Other (income)/deductions—net follow:
			Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
	(MILLIONS OF DOLLARS)		2014			2013			2014			2013
	Royalty-related income		$	(7	)	$	(8	)	$	(21	)	$	(21	)
	Identifiable intangible asset impairment charges(a)		6			—			6			1
	Net gain on sale of assets(b)		—			—			(6		)	(6		)
	Certain legal and other matters, net(c)		(1		)	1			10			1
	Foreign currency loss(d)		7			—			23			12
	Other, net(e)		(1		)	1			1			2
	Other (income)/deductions—net		$	4		$	(6	)	$	13		$	(11	)
	(a)	For the three and nine months ended September 28, 2014, reflects the impairment of IPR&D assets, related to a pharmaceutical product for dogs acquired with the FDAH acquisition in 2009, as a result of the termination of the development program due to a re-assessment of economic viability.
	(b)	For the nine months ended September 28, 2014, represents the net gain on sale of land in our Taiwan joint venture. For the nine months ended September 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.
	(c)	In July 2014, we reached a commercial settlement with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy. We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. The nine months ended September 28, 2014, includes a $13 million charge recorded in the second quarter of 2014, which was partially offset by a $1 million insurance recovery recorded in the third quarter of 2014. We do not expect any significant additional charges related to this issue. The nine months ended September 28, 2014, also includes an insurance recovery of other litigation-related charges.
	(d)	For the three and nine months ended September 28, 2014, primarily driven by costs related to hedging and exposures to certain emerging market currencies. The nine months ended September 28, 2014, also includes losses related to the depreciation of the Argentine peso in the first quarter of 2014. For the nine months ended September 29, 2013, primarily related to the Venezuela currency devaluation in February 2013.
	(e)	For the nine months ended September 28, 2014, includes a pension plan settlement charge related to the sale of a manufacturing plant, partially offset by interest income and other miscellaneous income.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 28, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	A.	Taxes on Income
	The effective tax rate was 29.8% for the third quarter of 2014, compared with 29.2% for the third quarter of 2013. The higher effective tax rate for the third quarter of 2014 compared with the third quarter of 2013 was primarily attributable to changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs.
	The effective tax rate was 30.7% for the first nine months of 2014, compared with 29.3% for the first nine months of 2013. The higher effective tax rate for the first nine months of 2014 compared with the first nine months of 2013 was primarily attributable to:
	•	an $8 million discrete tax expense during the first quarter of 2014 related to a prior period intercompany inventory adjustment;
	•	changes in the jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs; and
	•	a $2 million discrete income tax benefit during the first quarter of 2013 related to the 2012 U.S. research and development tax credit, which was retroactively extended on January 3, 2013.
	As of the Separation date, we operate under a new standalone legal entity structure. In connection with the Separation, adjustments have been made to the income tax accounts. See Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
	B.	Tax Matters Agreement
	In connection with the Separation, we entered into a tax matters agreement with Pfizer that governs the parties' respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. For additional information, see below and Note 17. Transactions and Agreements with Pfizer.
	In connection with this agreement and the Separation, our income tax accounts reflect Separation Adjustments, including significant adjustments to the deferred income tax asset and liability accounts and the tax liabilities associated with uncertain tax positions. For additional information, see below and Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation.
	In general, under the agreement:
	•	Pfizer is responsible for any U.S. federal, state, local or foreign income taxes and any U.S. state or local non-income taxes (and any related interest, penalties or audit adjustments and including those taxes attributable to our business) reportable on a consolidated, combined or unitary return that includes Pfizer or any of its subsidiaries (and us and/or any of our subsidiaries) for any periods or portions thereof ending on or prior to December 31, 2012. We are responsible for the portion of any such taxes for periods or portions thereof beginning on or after January 1, 2013, as would be applicable to us if we filed the relevant tax returns on a standalone basis.
	•	We are responsible for any U.S. federal, state, local or foreign income taxes and any U.S. state or local non-income taxes (and any related interest, penalties or audit adjustments) that are reportable on returns that include only us and/or any of our subsidiaries, for all tax periods whether before or after the completion of the Separation.
	•	Pfizer is responsible for certain specified foreign taxes directly resulting from certain aspects of the Separation.
	We will not generally be entitled to receive payment from Pfizer in respect of any of our tax attributes or tax benefits or any reduction of taxes of Pfizer. Neither party's obligations under the agreement will be limited in amount or subject to any cap. The agreement also assigns responsibilities for administrative matters, such as the filing of returns, payment of taxes due, retention of records and conduct of audits, examinations or similar proceedings. In addition, the agreement provides for cooperation and information sharing with respect to tax matters.
	Pfizer is primarily responsible for preparing and filing any tax return with respect to the Pfizer affiliated group for U.S. federal income tax purposes and with respect to any consolidated, combined, unitary or similar group for U.S. state or local or foreign income tax purposes or U.S. state or local non-income tax purposes that includes Pfizer or any of its subsidiaries, including those that also include us and/or any of our subsidiaries. We are generally be responsible for preparing and filing any tax returns that include only us and/or any of our subsidiaries.
	The party responsible for preparing and filing a given tax return will generally have exclusive authority to control tax contests related to any such tax return.
	C.	Deferred Taxes
	As of September 28, 2014, the total net deferred income tax liability of $115 million is included in Current deferred tax assets ($106 million), Noncurrent deferred tax assets ($55 million), Other current liabilities ($11 million) and Noncurrent deferred tax liabilities ($265 million).
	As of December 31, 2013, the total net deferred income tax liability of $177 million is included in Current deferred tax assets ($97 million), Noncurrent deferred tax assets ($63 million), Other current liabilities ($15 million) and Noncurrent deferred tax liabilities ($322 million).
	D.	Tax Contingencies
	As of September 28, 2014, the tax liabilities associated with uncertain tax positions of $54 million (exclusive of interest and penalties related to uncertain tax positions of $10 million) are included in Noncurrent deferred tax assets ($7 million) and Other taxes payable ($47 million).
	As of December 31, 2013, the tax liabilities associated with uncertain tax positions of $45 million (exclusive of interest related to uncertain tax positions of $11 million) are included in Noncurrent deferred tax assets ($6 million) and Other taxes payable ($39 million).
	Our tax liabilities for uncertain tax positions relate primarily to issues common among multinational corporations. Any settlements or statute of limitations expirations could result in a significant decrease in our uncertain tax positions. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. We do not expect that within the next twelve months any of our uncertain tax positions could significantly decrease as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of uncertain tax positions and potential tax benefits may not be representative of actual outcomes, and any variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income/(Loss)	9 Months Ended
	Sep. 28, 2014
Equity [Abstract]	'
Accumulated Other Comprehensive Loss	'
	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests
	Changes, net of tax, in accumulated other comprehensive loss follow:
			Currency Translation
			Adjustment			Benefit Plans				Accumulated Other
			Net Unrealized			Actuarial				Comprehensive
	(MILLIONS OF DOLLARS)		Gains/(Losses)			Gains/(Losses)				Loss
	Balance, December 31, 2013		$	(212	)	$	(7	)		$	(219	)
	Other comprehensive income (loss), net of tax		(20		)	2			(a)	(18		)
	Pension plan transfers from Pfizer Inc.(b)		—			(3		)		(3		)
	Balance, September 28, 2014		$	(232	)	$	(8	)		$	(240	)
	(a)	Includes the first quarter 2014 settlement charge associated with the 2012 sale of our Netherlands manufacturing facility. See Note 12. Benefit Plans.
	(b)	Reflects the 2014 transfers of defined benefit pension plans from Pfizer Inc. and the associated reclassification from Additional Paid in Capital to Accumulated other Comprehensive Loss. See Note 12 Benefit Plans.

Financial_Instruments

Financial Instruments	9 Months Ended
	Sep. 28, 2014
Financial Instruments [Abstract]	'
Financial Instruments	'
	Financial Instruments
	A.	Debt
	Credit Facilities
	In December 2012, we entered into a revolving credit agreement with a syndicate of banks providing for a five-year $1.0 billion senior unsecured revolving credit facility (the credit facility), which became effective in February 2013 upon the completion of the IPO and expires in December 2017. Subject to certain conditions, we have the right to increase the credit facility to up to $1.5 billion. The credit facility contains a financial covenant requiring us to not exceed a maximum total leverage ratio (the ratio of consolidated net debt as of the end of the period to consolidated Earnings Before Interest, Income Taxes, Depreciation and Amortization (EBITDA) for such period) of 3.95:1 for fiscal year 2014, 3.50:1 for fiscal year 2015 and 3.00:1 thereafter. The credit facility also contains a financial covenant requiring that we maintain a minimum interest coverage ratio (the ratio of EBITDA at the end of the period to interest expense for such period) of 3.50:1. In addition, the credit facility contains other customary covenants. We were in compliance with all financial covenants as of September 28, 2014, and December 31, 2013. There were no amounts drawn under the credit facility as of September 28, 2014, or December 31, 2013.
	We have additional lines of credit and other credit arrangements with a group of banks and other financial intermediaries for general corporate purposes. We maintain cash and cash equivalent balances in excess of our outstanding short-term borrowings. As of September 28, 2014, we had access to $73 million of lines of credit which expire at various times through 2017. Short-term borrowings outstanding related to these facilities were $10 million and $15 million as of September 28, 2014, and December 31, 2013, respectively. Long-term borrowings outstanding related to these facilities were $2 million as of both September 28, 2014, and December 31, 2013.
	Commercial Paper Program
	In February 2013, we entered into a commercial paper program with a capacity of up to $1.0 billion. As of September 28, 2014, and December 31, 2013, there was no commercial paper issued under this program.
	Short-Term Borrowings
	There were short-term borrowings of $10 million and $15 million as of September 28, 2014, and December 31, 2013, respectively (see Credit Facilities). The weighted-average interest rate on short-term borrowings outstanding was 8.0% and 5.7% for the periods ended September 28, 2014, and December 31, 2013, respectively.
	Senior Notes Offering and Other Long-Term Debt
	On January 28, 2013, we issued $3.65 billion aggregate principal amount of our senior notes (the senior notes offering) in a private placement, with an original issue discount of $10 million. The senior notes are comprised of $400 million aggregate principal amount of our 1.150% senior notes due 2016, $750 million aggregate principal amount of our 1.875% senior notes due 2018, $1.35 billion aggregate principal amount of our 3.250% senior notes due 2023 and $1.15 billion aggregate principal amount of our 4.700% senior notes due 2043.
	We sold $2.65 billion aggregate principal amount of our senior notes through the initial purchasers in the senior notes offering and Pfizer transferred $1.0 billion aggregate principal amount of our senior notes to certain of the initial purchasers, who sold such senior notes in the senior notes offering.
	The senior notes are governed by an indenture and supplemental indenture (collectively, the indenture) between us and Deutsche Bank Trust Company Americas, as trustee. The indenture contains certain covenants, including limitations on our and certain of our subsidiaries' ability to incur liens or engage in sale-leaseback transactions. The indenture also contains restrictions on our ability to consolidate, merge or sell substantially all of our assets. In addition, the indenture contains other customary terms, including certain events of default, upon the occurrence of which the senior notes may be declared immediately due and payable.
	Pursuant to the indenture, we are able to redeem the senior notes, in whole or in part, at any time by paying a “make whole” premium, plus accrued and unpaid interest to, but excluding, the date of redemption. Pursuant to our tax matters agreement with Pfizer, we will not be permitted to redeem the 2023 notes pursuant to this optional redemption provision, except under limited circumstances. Upon the occurrence of a change of control of us and a downgrade of the senior notes below an investment grade rating by each of Moody's Investors Service, Inc. and Standard & Poor's Ratings Services, we are, in certain circumstances, required to make an offer to repurchase all of the outstanding senior notes at a price equal to 101% of the aggregate principal amount of the senior notes together with accrued and unpaid interest to, but excluding, the date of repurchase.
	In connection with the senior notes offering, we entered into a registration rights agreement (Registration Rights Agreement) with the representatives of the initial purchasers of the senior notes. Pursuant to the terms of the Registration Rights Agreement, we were obligated, among other things, to use our commercially reasonable efforts to file a registration statement with the SEC enabling holders of the senior notes to exchange the privately placed notes for publicly registered notes with substantially the same terms. We filed the registration statement with the SEC on September 13, 2013, the SEC declared the registration statement effective on September 24, 2013, and the exchange offer was completed on October 31, 2013.
	The components of our long-term debt follow:
			September 28,			December 31,
	(MILLIONS OF DOLLARS)		2014			2013
	Lines of credit, due 2016-2017		$	2		$	2
	1.150% Senior Notes due 2016		400			400
	1.875% Senior Notes due 2018		750			750
	3.250% Senior Notes due 2023		1,350			1,350
	4.700% Senior Notes due 2043		1,150			1,150
			3,652			3,652
	Unamortized debt discount		(10		)	(10		)
	Long-term debt		$	3,642		$	3,642
	The fair value of our long-term debt was $3,648 million and $3,526 million as of September 28, 2014, and December 31, 2013, respectively, and has been determined using a third-party matrix-pricing model that uses significant inputs derived from, or corroborated by, observable market data and Zoetis’s credit rating (Level 2 inputs).
	The principal amount of long-term debt outstanding as of September 28, 2014, matures in the following years:
															After
	(MILLIONS OF DOLLARS)		2015			2016			2017		2018		2019		2019		Total
	Maturities		$	—		$	401		$	1	$	750	$	—	$	2,500	$	3,652
	Interest Expense
	Interest expense, net of capitalized interest, was $29 million and $87 million for the three and nine months ended September 28, 2014, respectively, and $29 million and $83 million for the three and nine months ended September 29, 2013, respectively. Capitalized interest was $1 million and $3 million for the three and nine months ended September 28, 2014, respectively, and $1 million and $2 million for the three and nine months ended September 29, 2013, respectively.
	B.	Derivative Financial Instruments
	Foreign Exchange Risk
	A significant portion of our revenue, earnings and net investment in foreign affiliates is exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenue in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk is also managed through the use of derivative financial instruments. These financial instruments serve to protect net income against the impact of the translation into U.S. dollars of certain foreign exchange-denominated transactions. The aggregate notional amount of foreign exchange derivative financial instruments offsetting foreign currency exposures was $1.1 billion and $1.4 billion, as of September 28, 2014, and December 31, 2013, respectively. The derivative financial instruments primarily offset exposures in the euro, the Brazilian real and the Australian dollar. The vast majority of the foreign exchange derivative financial instruments mature within 60 days and all mature within 180 days.
	All derivative contracts used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the condensed consolidated balance sheet. The company has not designated the foreign currency forward-exchange contracts as hedging instruments. We recognize the gains and losses on forward-exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.
	Fair Value of Derivative Instruments
	The location and fair values of derivative instruments not designated as hedging instruments are as follows:
			Fair Value of Derivatives
			September 28,			December 31,
	(MILLIONS OF DOLLARS)	Balance Sheet Location	2014			2013
	Foreign currency forward-exchange contracts	Other current assets	$	4		$	10
	Foreign currency forward-exchange contracts	Other current liabilities	(4		)	(5		)
	Total foreign currency forward-exchange contracts		$	—		$	5
	We use a market approach in valuing financial instruments on a recurring basis. Our derivative financial instruments are measured at fair value on a recurring basis using Level 2 inputs in the calculation of fair value.
	The net gains and losses incurred on foreign currency forward-exchange contracts not designated as hedging instruments were losses of less than $1 million and $1 million for the three and nine months ended September 28, 2014, respectively, and gains of $13 million and $32 million for the three and nine months ended September 29, 2013, respectively, and are recorded in Other (income)/deductions—net. These amounts were substantially offset in Other (income)/deductions—net by the effect of changing exchange rates on the underlying foreign currency exposures.

Inventories

Inventories	9 Months Ended
	Sep. 28, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	Inventories
	The components of inventory follow:
		September 28,		December 31,
	(MILLIONS OF DOLLARS)	2014		2013
	Finished goods	$	829	$	862
	Work-in-process	277		218
	Raw materials and supplies	282		213
	Inventories	$	1,388	$	1,293

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Other Intangible Assets	'
	Goodwill and Other Intangible Assets
	A.	Goodwill
	The components of, and changes in, the carrying amount of goodwill follow:
	(MILLIONS OF DOLLARS)		U.S.		EuAfME			CLAR		APAC		Total
	Balance, December 31, 2013		$	501	$	157		$	162	$	162	$	982
	Other(a)		—		(1		)	—		1		—
	Balance, September 28, 2014		$	501	$	156		$	162	$	163	$	982
	(a)	Primarily reflects adjustments for foreign currency translation.
	The gross goodwill balance was $1,518 million as of September 28, 2014, and December 31, 2013. Accumulated goodwill impairment losses (generated entirely in fiscal 2002) were $536 million as of September 28, 2014, and December 31, 2013.
	B.	Other Intangible Assets
	The components of identifiable intangible assets follow:
			As of September 28, 2014							As of December 31, 2013
								Identifiable							Identifiable
								Intangible							Intangible
			Gross					Assets, Less		Gross					Assets, Less
			Carrying		Accumulated			Accumulated		Carrying		Accumulated			Accumulated
	(MILLIONS OF DOLLARS)		Amount		Amortization			Amortization		Amount		Amortization			Amortization
	Finite-lived intangible assets:
	Developed technology rights		$	762	$	(253	)	$	509	$	762	$	(219	)	$	543
	Brands		216		(108		)	108		216		(100		)	116
	Trademarks and trade names		60		(40		)	20		59		(38		)	21
	Other		120		(117		)	3		121		(116		)	5
	Total finite-lived intangible assets		1,158		(518		)	640		1,158		(473		)	685
	Indefinite-lived intangible assets:
	Brands		39		—			39		39		—			39
	Trademarks and trade names		67		—			67		67		—			67
	In-process research and development(a)		3		—			3		12		—			12
	Product rights(b)		8		—			8		—		—			—
	Total indefinite-lived intangible assets		117		—			117		118		—			118
	Identifiable intangible assets		$	1,275	$	(518	)	$	757	$	1,276	$	(473	)	$	803
	(a) The in-process research and development (IPR&D) balance as of September 28, 2014, reflects the impairment of IPR&D assets, related to a pharmaceutical product for dogs acquired with the FDAH acquisition in 2009, as a result of the termination of the development program due to a re-assessment of economic viability.
	(b)	Product registration and application rights which were acquired from Pfizer in the third quarter of 2014. See Note 17. Transactions and Agreements with Pfizer.
	C.	Amortization
	Amortization expense related to acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in Amortization of intangible assets as it benefits multiple business functions. Amortization expense related to acquired intangible assets that are associated with a single function is included in Cost of sales, Selling, general and administrative expenses or Research and development expenses, as appropriate. Total amortization expense for finite-lived intangible assets was $15 million and $47 million for the three and nine months ended September 28, 2014, respectively, and $16 million and $47 million for the three and nine months ended September 29, 2013, respectively.

Benefit_Plans

Benefit Plans	9 Months Ended
	Sep. 28, 2014
Compensation and Retirement Disclosure [Abstract]	'
Benefit Plans	'
	Benefit Plans
	Prior to the Separation from Pfizer, employees who met certain eligibility requirements participated in various defined benefit pension plans and postretirement plans administered and sponsored by Pfizer. Effective December 31, 2012, our employees ceased to participate in the Pfizer U.S. qualified defined benefit and U.S. retiree medical plans, and liabilities associated with our employees under these plans were retained by Pfizer. Pfizer is continuing to credit certain employees' service with Zoetis generally through December 31, 2017 (or termination of employment from Zoetis, if earlier) for certain early retirement benefits with respect to Pfizer's U.S. defined benefit pension and retiree medical plans. Pension and postretirement benefit expense associated with the extended service for certain employees in the U.S. plans totaled approximately $2 million and $5 million for the three and nine months ended September 28, 2014, respectively, and $1 million and $5 million for the three and nine months ended September 29, 2013, respectively.
	As part of the Separation, certain Separation Adjustments (see Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer: Adjustments Associated with the Separation) were made to transfer the assets and liabilities of certain international defined benefit pension plans to Zoetis in the first quarter of 2013, and we assumed the liabilities allocable to employees transferring to us. Prior to the Separation, these benefit plans were accounted for as multi-employer plans. Also, as part of the Separation, a net liability was recognized in 2013 for the pension obligations less the fair value of plan assets associated with additional defined benefit pension plans in certain international locations that were expected to be transferred to us in 2014 (approximately $21 million), in accordance with the applicable local separation agreements or employee matters agreement. During the first quarter of 2014, our pension plan in Japan was transferred to us from Pfizer. The net pension obligation (approximately $2 million) and the related accumulated other comprehensive loss (approximately $2 million, net of tax) associated with this plan were recorded. During the third quarter of 2014, our pension plans in Australia and Switzerland were transferred to us from Pfizer and the combined net pension obligations (approximately $1 million) and the related accumulated other comprehensive loss (approximately $1 million, net of tax) associated with these plans were recorded. The $21 million net liability recognized in 2013 was reduced to approximately $18 million, the balance as of September 28, 2014. We expect the pension plan in Belgium to transfer to us in the fourth quarter of 2014 and the pension plan in the Philippines to transfer to us in 2015.
	Pension expense associated with our dedicated international pension plans was approximately $2 million and $9 million for the three and nine months ended September 28, 2014, respectively, and $1 million and $3 million for the three and nine months ended September 29, 2013, respectively. The nine months ended September 28, 2014, includes a settlement charge of approximately $4 million (approximately $3 million, net of tax) associated with the 2012 sale of our Netherlands manufacturing facility. The active participants in the plan were transferred to the buyer at the time of sale and the plan liability associated with inactive participants remained with the insurance contract that was used to finance the plan. The insurance contract was also transferred to the buyer although we remained liable for the proportion of administrative costs that related to inactive members under the terms of this contract through December 31, 2013. Under the terms of the sale agreement, the contract was terminated on December 31, 2013 (fiscal year 2014 for our international operations) and the liability for benefits associated with this plan reverted in full to the insurance company.
	Pension expense associated with international benefit plans accounted for as multi-employer plans was approximately $1 million and $4 million for the three and nine months ended September 28, 2014, respectively, and $2 million and $7 million for the three and nine months ended September 29, 2013, respectively.
	Total contributions to the dedicated and multi-employer plans were approximately $2 million and $6 million for the three and nine months ended September 28, 2014, respectively, and $2 million and $8 million for the three and nine months ended September 29, 2013, respectively. We expect to contribute a total of approximately $8 million to these plans in 2014.

Sharebased_Payments

Share-based Payments	9 Months Ended
	Sep. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-based Payments	'
	Share-Based Payments
	The company may grant a variety of share-based payments under the Zoetis 2013 Equity and Incentive Plan (Equity Plan) to employees and non-employee directors. The principal types of share-based awards available under the Equity Plan may include, but are not limited to, stock options, restricted stock and restricted stock units (RSUs), deferred stock unit awards (DSUs), performance-based awards and other equity-based or cash-based awards.
	The components of share-based compensation expense follow:
		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,		September 29,
	(MILLIONS OF DOLLARS)	2014		2013		2014		2013
	Stock options / stock appreciation rights	$	5	$	3	$	12	$	7
	RSUs / DSUs	4		3		10		5
	Pfizer stock benefit plans	—		—		—		25
	Share-based compensation expense—total	$	9	$	6	$	22	$	37
	During the nine months ended September 28, 2014, the company granted 3,006,351 stock options with a weighted-average exercise price of $30.97 per stock option and a weighted-average fair value of $8.01 per option. The fair-value based method for valuing each Zoetis stock option grant on the grant date uses the Black-Scholes-Merton option-pricing model, which incorporates a number of valuation assumptions. The weighted-average fair value was estimated based on the following assumptions: risk-free interest rate of 2.01%; expected dividend yield of 0.93%; expected stock price volatility of 24.7%; and expected term of 6.5 years. The values determined through this fair-value based method generally are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
	During the nine months ended September 28, 2014, the company granted 837,990 RSUs with a weighted-average grant date fair value of $30.99 per RSU. RSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. In general, RSUs vest after three years of continuous service from the grant date and the values are amortized on a straight-line basis over the vesting term into Cost of sales, Selling, general and administrative expenses, or Research and development expenses, as appropriate.
	During the nine months ended September 28, 2014, the company granted 36,256 DSUs with a weighted-average grant date fair value of $30.89 per DSU. DSUs are accounted for using a fair-value-based method that utilizes the closing price of Zoetis common stock on the date of grant. DSUs vest immediately as of the grant date and the values are expensed at the time of grant into Selling, general and administrative expenses.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 28, 2014
Earnings Per Share [Abstract]	'
Earnings per Share	'
	Earnings per Share
	The following table presents the calculation of basic and diluted earnings per share:
		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,		September 29,
	(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	2014		2013		2014		2013
	Numerator
	Net income before allocation to noncontrolling interests	$	167	$	131	$	461	$	399
	Less: net income attributable to noncontrolling interests	1		—		4		—
	Net income attributable to Zoetis Inc.	$	166	$	131	$	457	$	399
	Denominator
	Weighted-average common shares outstanding	501.453		500		500.887		500
	Common stock equivalents: stock options, RSUs and DSUs	0.992		0.354		0.723		0.227
	Weighted-average common and potential dilutive shares outstanding	502.445		500.354		501.61		500.227
	Earnings per share attributable to Zoetis Inc. stockholders—basic	$	0.33	$	0.26	$	0.91	$	0.8
	Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	0.33	$	0.26	$	0.91	$	0.8
	As of September 28, 2014, and September 29, 2013, there were approximately 3 million and 2 million stock options outstanding, respectively, under the company’s Equity Plan that were excluded from the computation of diluted earnings per share, as the effect would have been antidilutive.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 7. Income Taxes.
	A.	Legal Proceedings
	Our non-tax contingencies include, among others, the following:
	•	Product liability and other product-related litigation, which can include injury, consumer, off-label promotion, antitrust and breach of contract claims.
	•	Commercial and other matters, which can include product-pricing claims and environmental claims and proceedings.
	•	Patent litigation, which typically involves challenges to the coverage and/or validity of our patents or those of third parties on various products or processes.
	•	Government investigations, which can involve regulation by national, state and local government agencies in the United States and in other countries.
	Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial.
	We believe that we have strong defenses in these types of matters, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations or cash flows in the period in which the amounts are paid.
	We have accrued for losses that are both probable and reasonably estimable. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.
	Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.
	The principal matters to which we are a party are discussed below. In determining whether a pending matter is significant for financial reporting and disclosure purposes, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be a class action and our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information about the company that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters, we consider, among other things, the financial significance of the product protected by the patent.
	Roxarsone®(3-Nitro)
	We are defendants in nine actions involving approximately 140 plaintiffs that allege that the distribution of the medicated feed additive Roxarsone allegedly caused various diseases in the plaintiffs, including cancers and neurological diseases. Other defendants, including various poultry companies, are also named in these lawsuits. Compensatory and punitive damages are sought in unspecified amounts.
	In September 2006, the Circuit Court of Washington County returned a defense verdict in one of the lawsuits, Mary Green, et al. v. Alpharma, Inc. et al. In 2008, this verdict was appealed and affirmed by the Arkansas Supreme Court. Certain summary judgments favoring the poultry company co-defendants in Mary Green, et al. v. Alpharma, Inc. et al. were reversed by the Arkansas Supreme Court in 2008. These claims were retried in 2009 and that trial also resulted in a defense verdict, which was affirmed by the Arkansas Supreme Court in April 2011. In October 2012, we entered into an agreement to resolve these cases, subject to the execution of full releases or dismissals with prejudice by all of the claimants. We received full releases from all claimants, and as a result, on January 23, 2014, the Court dismissed all nine actions with prejudice.
	In June 2011, we announced that we would suspend sales in the United States of Roxarsone (3-Nitro) in response to a request by the U.S. FDA and subsequently stopped sales in several international markets.
	Following our decision to suspend sales of Roxarsone (3-Nitro) in June 2011, Zhejiang Rongyao Chemical Co., Ltd., the supplier of certain materials used in the production of Roxarsone (3-Nitro), filed a lawsuit in the U.S. District Court for the District of New Jersey alleging that we are liable for damages it suffered as a result of the decision to suspend sales. In October 2013, the parties reached a preliminary agreement to resolve the matter, and the Court dismissed the action with prejudice. In December 2013, the parties finalized and executed the settlement agreement.
	PregSure®
	We have received in total approximately 240 claims in Europe and New Zealand seeking damages related to calves claimed to have died of Bovine Neonatal Pancytopenia (BNP) on farms where PregSure BVD, a vaccine against Bovine Virus Diarrhea (BVD) was used. BNP is a rare syndrome that first emerged in cattle in Europe in 2006. Studies of BNP suggest a potential association between the administration of PregSure and the development of BNP, although no causal connection has been established. The cause of BNP is not known.
	In 2010, we voluntarily stopped sales of PregSure BVD in Europe, and recalled the product at wholesalers while investigations into possible causes of BNP continue. In 2011, after incidences of BNP were reported in New Zealand, we voluntarily withdrew the marketing authorization for PregSure throughout the world.
	We have settled approximately 128 of these claims for amounts that are not material individually or in the aggregate. Investigations into possible causes of BNP continue and these settlements may not be representative of any future claims resolutions.
	Advocin
	On January 30, 2012, Bayer filed a complaint against Pfizer alleging infringement and inducement of infringement of Bayer U.S. patent No. 5,756,506 covering, among other things, a process for treating bovine respiratory disease (BRD) by administering a single high dose of fluoroquinolone. The complaint was filed after our product Advocin® was approved as a single dose treatment of BRD, in addition to its previous approval as a multi-dose treatment of BRD. Bayer seeks a permanent injunction, damages and a recovery of attorney's fees, and has demanded a jury trial. Discovery has now concluded. We have filed motions for summary judgment of non-infringement and invalidity of the Bayer patent, which are currently pending before the Court.
	Ulianopolis, Brazil
	In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL) and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup.
	The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. We believe we have strong arguments against the claim, including defense strategies against any claim of joint and several liability.
	At the request of the Municipal prosecutor, in April 2012, the lawsuit was suspended for one year. Since that time, the prosecutor has initiated investigations into the Municipality's actions in the matter as well as the efforts undertaken by the six defendants to remove and dispose of their individual waste from the incineration facility. The Municipal prosecutor held a meeting on October 3, 2014, in which it was announced there is no final outcome for the investigation as yet. Each defendant was called to verify tax documentation and provide comments on a proposed Term of Reference by January 2015.
	In early August 2013, new labor claims were filed against FDSAL as well as 57 other companies. These claims were filed by 30 employees of the local waste incineration facility that was used by FDSAL and the 57 other companies. The employees of the incineration facility allege that FDSAL and the other users of the facility are severally liable for health injuries suffered in connection with plaintiffs’ employment at the waste site. Based on legal precedent, it is possible that FDSAL may be considered a liable party. The plaintiffs' lawyers presented a motion for discontinuance of these 30 labor claims during the hearing held on December 9, 2013, because (i) not all defendants had been summoned which would generate delays in the proceedings and preliminaries of lawsuits' dismissal; and (ii) the pieces of evidence for each claim shall be more concentrated. The court dismissed the cases on the same date.
	Other Matters
	The European Commission published a decision on alleged competition law infringements by several human health pharmaceutical companies on June 19, 2013. One of the involved legal entities is Zoetis Products LLC, formerly having the name Alpharma Inc. Zoetis Products LLC's involvement is solely related to its human health activities prior to Pfizer's acquisition of King/Alpharma. Zoetis paid a fine in the amount of Euro 11 million (approximately $14 million) and was reimbursed by Pfizer in accordance with the Global Separation Agreement between Pfizer and Zoetis, which provides that Pfizer is obligated to indemnify Zoetis for any liabilities arising out of claims not related to its animal health assets. We filed an appeal of the decision on September 6, 2013.
	In July 2014, we reached a commercial settlement with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy. We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. We recorded a $13 million charge in Other (income)/deductions—net in the second quarter of 2014, and we do not expect any significant additional charges related to this issue. In the third quarter of 2014, we were notified of an insurance recovery of $1 million and have recorded this in Other (income)/deductions—net.
	B.	Guarantees and Indemnifications
	In the ordinary course of business and in connection with the sale of assets and businesses, we indemnify our counterparties against certain liabilities that may arise in connection with the transaction or related to activities prior to the transaction. These indemnifications typically pertain to environmental, tax, employee and/or product-related matters and patent-infringement claims. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we would be required to reimburse the loss. These indemnifications are generally subject to threshold amounts, specified claim periods and other restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of September 28, 2014, recorded amounts for the estimated fair value of these indemnifications are not significant.

Segment_and_Other_Revenue_Info

Segment and Other Revenue Information	9 Months Ended
	Sep. 28, 2014
Segment Reporting [Abstract]	'
Segment and Other Revenue Information	'
	Segment and Other Revenue Information
	A.	Segment Information
	In the first quarter of 2014, we realigned our segment reporting with respect to our Client Supply Services (CSS) organization, which provides contract manufacturing services to third parties, to reflect how our chief operating decision maker currently evaluates our financial results. The revenue and earnings associated with CSS are now reported within Other business activities, separate from our four reportable segments. In 2013, CSS results were reported in the EuAfME segment. The current presentation of segments is more reflective of our commercial business since CSS operates differently from our commercial operations within the geographic segments. CSS revenue for the first, second, third and fourth quarters of 2013, including livestock (LS) and companion animal (CA) revenue, was $11 million (LS - $3 million; CA - $8 million), $12 million (LS - $3 million; CA - $9 million), $14 million (LS - $4 million; CA - $10 million) and $16 million (LS - $5 million; CA - $11 million), respectively. CSS earnings (loss) for the first, second, third and fourth quarters of 2013 were $3 million, $(2) million, $2 million and $5 million, respectively. We have revised our segment results presented herein to reflect this new segment structure, including for the comparable 2013 periods.
	The animal health medicines and vaccines industry is characterized by meaningful differences in customer needs across different regions. As a result of these differences, among other things, we manage our operations through four geographic regions. Each operating segment has responsibility for its commercial activities. Within each of these regional operating segments, we offer a diversified product portfolio, including vaccines, parasiticides, anti-infectives, medicated feed additives and other pharmaceuticals, for both livestock and companion animal customers.
	Operating Segments
	•	The U.S.
	•	EuAfME—Includes, among others, the United Kingdom, Germany, France, Italy, Spain, Northern Europe and Central Europe as well as Russia, Turkey and South Africa.
	•	CLAR––Includes Canada, Brazil, Mexico, Central America and other South American countries.
	•	APAC––Includes Australia, Japan, New Zealand, South Korea, India, China/Hong Kong, Northeast Asia, Southeast Asia and South Asia.
	Our chief operating decision maker uses the revenue and earnings of the four operating segments, among other factors, for performance evaluation and resource allocation.
	Other Costs and Business Activities
	Certain costs are not allocated to our operating segment results, such as costs associated with the following:
	•	Other business activities includes our CSS contract manufacturing results, as well as expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the respective regional segment.
	•	Corporate, which is responsible for platform functions such as business technology, facilities, legal, finance, human resources, business development, public affairs and procurement, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
	•	Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition-related activities, where we incur costs for restructuring and integration; and (iii) Certain significant items, which includes non-acquisition-related restructuring charges, certain asset impairment charges, stand-up costs and costs associated with cost reduction/productivity initiatives.
	•	Other unallocated includes certain overhead expenses associated with our global manufacturing operations not charged to our operating segments. Effective January 1, 2014, Other unallocated also includes certain costs associated with business technology and finance that specifically support our global manufacturing operations. These costs were previously reported in Corporate. Also, beginning in the first quarter of 2014, certain supply chain and global logistics costs that were previously reported in the four reportable segments are reported in Other unallocated. This presentation better reflects how we measure the performance of the global manufacturing organization.
	Segment Assets
	We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $6.5 billion and $6.6 billion at September 28, 2014, and December 31, 2013, respectively.
	Selected Statement of Income Information
													Depreciation and
			Revenue(a)				Earnings(b)						Amortization(c)
			September 28,		September 29,		September 28,			September 29,			September 28,		September 29,
	(MILLIONS OF DOLLARS)		2014		2013		2014			2013			2014		2013
	Three months ended
	U.S.		$	532	$	495	$	313		$	285		$	7	$	11
	EuAfME		293		256		116			90			5		5
	CLAR		194		171		68			56			4		5
	APAC		179		167		71			57			4		4
	Total reportable segments		1,198		1,089		568			488			20		25
	Other business activities(d)		12		14		(75		)	(78		)	7		6
	Reconciling Items:
	Corporate(e)		—		—		(145		)	(139		)	7		4
	Purchase accounting adjustments(f)		—		—		(13		)	(12		)	13		12
	Acquisition-related costs(g)		—		—		(1		)	(1		)	—		—
	Certain significant items(h)		—		—		(38		)	(46		)	1		—
	Other unallocated(i)		—		—		(58		)	(27		)	2		2
			$	1,210	$	1,103	$	238		$	185		$	50	$	49
	Nine months ended
	U.S.		$	1,470	$	1,386	$	849		$	773		$	24	$	33
	EuAfME		847		801		331			297			15		15
	CLAR		576		555		220			186			10		14
	APAC		533		528		209			203			13		10
	Total reportable segments		3,426		3,270		1,609			1,459			62		72
	Other business activities(d)		39		37		(221		)	(225		)	21		21
	Reconciling Items:
	Corporate(e)		—		—		(398		)	(392		)	21		16
	Purchase accounting adjustments(f)		—		—		(38		)	(37		)	38		37
	Acquisition-related costs(g)		—		—		(5		)	(17		)	—		—
	Certain significant items(h)		—		—		(127		)	(130		)	4		—
	Other unallocated(i)		—		—		(155		)	(94		)	5		5
			$	3,465	$	3,307	$	665		$	564		$	151	$	151
	(a)	Revenue denominated in euros was $175 million and $525 million for the three and nine months ended September 28, 2014, respectively, and $159 million and $493 million for the three and nine months ended September 29, 2013, respectively.
	(b)	Defined as income before provision for taxes on income.
	(c)	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
	(d)	Other business activities reflects the research and development costs managed by our Research and Development organization, as well as our contract manufacturing business.
	(e)	Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
	(f)	Purchase accounting adjustments includes certain charges related to intangible assets and property, plant and equipment not charged to our operating segments.
	(g)	Acquisition-related costs can include costs associated with acquiring, integrating and restructuring acquired businesses, such as allocated transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
	(h)	Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain legal and commercial settlements and the impact of divestiture-related gains and losses. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisition and Cost-Reduction/Productivity Initiatives.
	•	In the third quarter of 2014, Certain significant items primarily includes: (i) Zoetis stand-up costs of $32 million; (ii) intangible asset impairment charges related to an IPR&D project acquired with the FDAH acquisition in 2009 of $6 million; and (iii) restructuring charges of $1 million related to employee severance costs in EuAfME. Stand-up costs include certain nonrecurring costs related to becoming an independent public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment costs.
	•	In the third quarter of 2013, Certain significant items primarily includes: (i) Zoetis stand-up costs of $41 million; and (ii) litigation-related charges of $5 million.
	•	In the nine months ended September 28, 2014, Certain significant items primarily includes: (i) Zoetis stand-up costs of $106 million; (ii) charges related to a commercial settlement in Mexico of $13 million, partially offset by the insurance recovery of $1 million income; (iii) restructuring charges of $6 million related to employee severance costs in EuAfME, partially offset by $2 million income related to a reversal of a previously established reserve as a result of a change in estimate of severance costs; (iv) intangible asset impairment charges related to an IPR&D project acquired with the FDAH acquisition in 2009 of $6 million; (v) the Zoetis portion of a net gain on the sale of land by our Taiwan joint venture of $3 million; (vi) additional depreciation associated with asset restructuring of $1 million; (vii) a pension plan settlement charge related to the divestiture of a manufacturing plant of $4 million; and (viii) an insurance recovery of litigation related charges of $2 million income.
	•	In the nine months ended September 29, 2013, Certain significant items primarily includes: (i) Zoetis stand-up costs of $152 million; (ii) $26 million income related to the reversal of certain employee termination expenses; (iii) $6 million income on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009; (iv) additional depreciation associated with asset restructuring of $3 million; and (v) litigation-related charges of $5 million.
(i)	Includes overhead expenses associated with our manufacturing operations.
B.	Other Revenue Information
Revenue by Species
Significant species revenue are as follows:
		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,			September 29,
(MILLIONS OF DOLLARS)		2014		2013		2014			2013
Livestock:
Cattle		$	437	$	387	$	1,207		$	1,132
Swine		179		154		496			463
Poultry		147		137		428			412
Other		27		24		68			65
		790		702		2,199			2,072
Companion Animal:
Horses		38		37		127			124
Dogs and Cats		370		350		1,100			1,074
		408		387		1,227			1,198
Contract Manufacturing		$	12	$	14	$	39		$	37
Total revenue		$	1,210	$	1,103	$	3,465		$	3,307
Revenue by Major Product Category
Significant revenue by major product category are as follows:
		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,			September 29,
(MILLIONS OF DOLLARS)		2014		2013		2014			2013
Anti-infectives		$	356	$	333	$	965		$	920
Vaccines		308		296		886			867
Parasiticides		178		156		528			519
Medicated feed additives		124		94		337			295
Other pharmaceuticals		200		175		598			555
Other non-pharmaceuticals		32		35		112			114
Contract manufacturing		12		14		39			37
Total revenue		$	1,210	$	1,103	$	3,465		$	3,307

Transactions_and_Agreements_wi

Transactions and Agreements with Pfizer	9 Months Ended
	Sep. 28, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Transactions and Agreements with Pfizer
	Zoetis had related party transactions with Pfizer through the completion of the Exchange Offer on June 24, 2013. As of the completion of the Exchange Offer, Pfizer is no longer a related party. Activities while Pfizer was a related party, as well as ongoing agreements with Pfizer, are detailed below.
	In connection with the Separation and IPO, we and Pfizer entered into agreements that provide a framework for our ongoing relationship with Pfizer, certain of which are described below.
	•	Global separation agreement. This agreement governs the relationship between Pfizer and us following the IPO and includes provisions related to the allocation of assets and liabilities, indemnification, delayed transfers and further assurances, mutual releases, insurance and certain covenants.
	•	Transitional services agreement. This agreement grants us the right to continue to use certain of Pfizer's services and resources related to our corporate functions, such as business technology, facilities, finance, human resources, public affairs and procurement, in exchange for mutually agreed-upon fees based on Pfizer's costs of providing these services.
	•	Tax matters agreement. This agreement governs ours and Pfizer's respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. Pursuant to this agreement, we have also agreed to certain covenants that contain restrictions intended to preserve the tax-free status of certain transactions, and we have agreed to indemnify Pfizer and its affiliates against any and all tax-related liabilities incurred by them relating to these transactions to the extent caused by an acquisition of our stock or assets or by any other action undertaken by us.
	•	Research and development collaboration and license agreement. This agreement permits certain of our employees to be able to review a Pfizer database to identify compounds that may be of interest to the animal health field. Pfizer has granted to us an option to enter into a license agreement subject to certain restrictions and requirements and we will make payments to Pfizer.
	•	Employee matters agreement. This agreement governs ours and Pfizer's respective rights, responsibilities and obligations with respect to the following matters: employees and former employees (and their respective dependents and beneficiaries) who are or were associated with Pfizer, us or the parties' respective subsidiaries or affiliates; the allocation of assets and liabilities generally relating to employees, employment or service-related matters and employee benefit plans; and other human resources, employment and employee benefits matters.
	•	Master manufacturing and supply agreements. These two agreements govern our manufacturing and supply arrangements with Pfizer. Under one of these agreements, Pfizer will manufacture and supply us with animal health products. Under this agreement, our manufacturing and supply chain leadership will have oversight responsibility over product quality and other key aspects of the manufacturing process with respect to the Pfizer-supplied products. Under the other agreement, we will manufacture and supply certain human health products to Pfizer.
	•	Environmental matters agreement. This agreement governs the performance of remedial actions for liabilities allocated to each party under the global separation agreement; addresses our substitution for Pfizer with respect to animal health assets and remedial actions allocated to us (including substitution related to, for example, permits, financial assurances and consent orders); allows our conditional use of Pfizer's consultants and contractors to assist in the conduct of remedial actions; and addresses the exchange of related information between the parties. The agreement also sets forth standards of conduct for remedial activities at the co-located facilities: Guarulhos, Brazil; Catania, Italy; Hsinchu, Taiwan; and Kalamazoo, Michigan in the United States. In addition, the agreement sets forth site-specific terms to govern conduct at several of these co-located facilities.
	•	Screening services agreement. This agreement requires us to provide certain high throughput screening services to Pfizer's R&D organization for which Pfizer pays to us agreed-upon fees.
	•	Intellectual property license agreements. Under these agreements (i) Pfizer and certain of its affiliates licensed to us and certain of our affiliates the right to use certain intellectual property rights in the animal health field; (ii) we licensed to Pfizer and certain of its affiliates certain rights to intellectual property in all fields outside of the animal health field; and (iii) Pfizer granted us rights with respect to certain trademarks and copyrighted works.
	Following the Separation, we own, have access to or have the right to use, substantially all of the resources that were used, or held for use, exclusively in Pfizer's animal health business, including the following:
	•	Intellectual Property. As part of the Separation, Pfizer assigned to us ownership of certain animal health related patents, pending patent applications, and trademark applications and registrations. In addition, Pfizer licensed to us the right to use certain intellectual property rights in the animal health field. We licensed to Pfizer the right to use certain of our trademarks and substantially all of our other intellectual property rights in the human health field and all other fields outside of animal health. In addition, Pfizer granted us a transitional license to use certain of Pfizer's trademarks and we granted Pfizer a transitional license to use certain of our trademarks for a period of time following the completion of the IPO.
	•	Manufacturing Facilities. Our global manufacturing network consists of 13 “anchor” manufacturing sites and 14 “satellite” manufacturing sites. Ownership of, or the existing leasehold interest in, these facilities were conveyed to us by Pfizer as part of the Separation. Among these 27 manufacturing sites is our facility in Guarulhos, Brazil, which we leased back to Pfizer. Certain of our products are currently manufactured at 13 manufacturing sites that were retained by Pfizer. The products manufactured by Pfizer at these sites and at our Guarulhos, Brazil facility continue to be supplied to us under the terms of a manufacturing and supply agreement we entered into with Pfizer.
	•	R&D Facilities. We have R&D operations co-located with certain of our manufacturing sites in Australia, Belgium, Brazil, China, Spain and the United States to facilitate the efficient transfer of production processes from our laboratories to manufacturing sites. In addition, we maintain R&D operations at non-manufacturing locations in Belgium, Brazil, India and the United States. As part of the Separation, Pfizer conveyed to us its interest in each of these R&D facilities, with the exception of our Mumbai, India facility, which we expect Pfizer to transfer to us after the completion of the Separation for cash consideration to be agreed upon, and, in the interim, we are leasing this facility from Pfizer.
	•	Employees. In general, as part of the Separation, employees of Pfizer who were substantially dedicated to the animal health business became our employees. However, labor and employment laws or other business considerations in some jurisdictions delayed Pfizer from transferring to us employees who are substantially dedicated to the animal health business. In those instances, to the extent permissible under applicable law, we and Pfizer entered into mutually-acceptable arrangements to provide for continued operation of the business until such time as the employees in those jurisdictions can be transferred to us.
	The amounts charged under each of the agreements with Pfizer, while Pfizer was still a related party, through the completion of the Exchange Offer on June 24, 2013, were as follows:
	(MILLIONS OF DOLLARS)
	Transitional services agreement		$	63
	Master manufacturing and supply agreements		$	130
	Employee matters agreement		$	99
	In certain jurisdictions, while the Zoetis entities obtain appropriate registration and licensing, Pfizer entities purchase product from Zoetis entities and resell such product to the local Zoetis entity at cost. This activity is reflected in Accounts receivable for the product Pfizer purchases from Zoetis entities and in Accounts payable for the product purchased from such Pfizer entities by our local Zoetis entity.
	During the third quarter of 2014, Zoetis and Pfizer entered into an agreement whereby Pfizer agreed to transfer certain product registration and application rights associated with our operations in Indonesia. The fair value of these rights, as agreed by both parties, was $8 million, payable by Zoetis to Pfizer in four annual installments of $2 million each, beginning in October 2014. At September 28, 2014, the fair value of these indefinite-lived intangible assets of approximately $8 million was included in Identifiable intangible assets, less accumulated amortization and the related payable to Pfizer was included in Other current liabilities ($2 million) and Other noncurrent liabilities ($6 million).
	At September 28, 2014, and December 31, 2013, $36 million and $121 million, respectively, was included in Accounts receivable as receivable from Pfizer, and $63 million and $181 million, respectively, was included in Accounts payable as payable to Pfizer.

Restructuring_Charges_and_Othe1

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	9 Months Ended
	Sep. 28, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Costs Associated with Cost-Reduction/Productivity Initiatives and Acquisition Activity	'
	The components of costs incurred in connection with restructuring initiatives, acquisitions and cost-reduction/productivity initiatives follow:
			Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
	(MILLIONS OF DOLLARS)		2014			2013			2014			2013
	Restructuring charges and certain acquisition-related costs:
	Integration costs(a)		$	1		$	3		$	5		$	16
	Restructuring charges(b):
	Employee termination costs		1			—			4			(26		)
	Accelerated depreciation		—			—			1			—
	Total Restructuring charges and certain acquisition-related costs		2			3			10			(10		)
	Other costs associated with cost-reduction/productivity initiatives:
	Additional depreciation associated with asset restructuring––direct(c)		—			—			—			1
	Additional depreciation associated with asset restructuring––allocated(c)		—			—			—			2
	Implementation costs––allocated(d)		—			—			—			1
	Total costs associated with acquisitions and cost-reduction/productivity initiatives		$	2		$	3		$	10		$	(6	)
	(a)	Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.
	(b)	The restructuring charges for the three and nine months ended September 28, 2014, include employee severance costs in EuAfME ($1 million and $6 million, respectively). Additionally, the nine months ended September 28, 2014, includes a reversal of a previously established reserve as a result of a change in estimate of severance costs ($2 million benefit), and accelerated depreciation related to the exiting of a research facility ($1 million). The restructuring benefit for the nine months ended September 29, 2013, is primarily related to the reversal of certain employee termination expenses associated with our operations in Europe.
	The restructuring charges/benefits are associated with the following:
	•	For the three months ended September 28, 2014––EuAfME ($1 million).
	•	For the nine months ended September 28, 2014––EuAfME ($6 million) and Manufacturing/research/corporate ($1 million benefit).
	•	For the nine months ended September 29, 2013––Manufacturing/research/corporate ($26 million benefit).
	(c)	Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended September 29, 2013, included in Cost of Sales ($1 million) and Selling, general and administrative expenses ($2 million).
	(d)	Implementation costs—allocated represent external, incremental costs directly related to implementing cost reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.
Schedule of Restructuring and Related Costs	'
	The components of and changes in our restructuring accruals follow:
			Employee
			Termination			Accelerated			Exit
	(MILLIONS OF DOLLARS)		Costs			Depreciation			Costs			Accrual
	Balance, December 31, 2013(a)		$	15		$	—		$	6		$	21
	Provision		4			1			—			5
	Utilization and other(b)		(7		)	(1		)	(3		)	(11		)
	Balance, September 28, 2014(a)		$	12		$	—		$	3		$	15
	(a)	At September 28, 2014, and December 31, 2013, included in Other current liabilities ($7 million and $13 million, respectively) and Other noncurrent liabilities ($7 million and $8 million, respectively).
	(b)	Includes adjustments for foreign currency translation.

Other_IncomeDeductions_Net_Tab

Other (Income)/Deductions - Net (Tables)	9 Months Ended
	Sep. 28, 2014
Other Income and Expenses [Abstract]	'
Components of Other (Income)/DeductionsbNet	'
	The components of Other (income)/deductions—net follow:
			Three Months Ended						Nine Months Ended
			September 28,			September 29,			September 28,			September 29,
	(MILLIONS OF DOLLARS)		2014			2013			2014			2013
	Royalty-related income		$	(7	)	$	(8	)	$	(21	)	$	(21	)
	Identifiable intangible asset impairment charges(a)		6			—			6			1
	Net gain on sale of assets(b)		—			—			(6		)	(6		)
	Certain legal and other matters, net(c)		(1		)	1			10			1
	Foreign currency loss(d)		7			—			23			12
	Other, net(e)		(1		)	1			1			2
	Other (income)/deductions—net		$	4		$	(6	)	$	13		$	(11	)
	(a)	For the three and nine months ended September 28, 2014, reflects the impairment of IPR&D assets, related to a pharmaceutical product for dogs acquired with the FDAH acquisition in 2009, as a result of the termination of the development program due to a re-assessment of economic viability.
	(b)	For the nine months ended September 28, 2014, represents the net gain on sale of land in our Taiwan joint venture. For the nine months ended September 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.
	(c)	In July 2014, we reached a commercial settlement with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy. We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. The nine months ended September 28, 2014, includes a $13 million charge recorded in the second quarter of 2014, which was partially offset by a $1 million insurance recovery recorded in the third quarter of 2014. We do not expect any significant additional charges related to this issue. The nine months ended September 28, 2014, also includes an insurance recovery of other litigation-related charges.
	(d)	For the three and nine months ended September 28, 2014, primarily driven by costs related to hedging and exposures to certain emerging market currencies. The nine months ended September 28, 2014, also includes losses related to the depreciation of the Argentine peso in the first quarter of 2014. For the nine months ended September 29, 2013, primarily related to the Venezuela currency devaluation in February 2013.
	(e)	For the nine months ended September 28, 2014, includes a pension plan settlement charge related to the sale of a manufacturing plant, partially offset by interest income and other miscellaneous income.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income/(Loss) (Tables)	9 Months Ended
	Sep. 28, 2014
Equity [Abstract]	'
Changes, Net of Tax, in Accumulated Other Comprehensive Loss	'
	Changes, net of tax, in accumulated other comprehensive loss follow:
			Currency Translation
			Adjustment			Benefit Plans				Accumulated Other
			Net Unrealized			Actuarial				Comprehensive
	(MILLIONS OF DOLLARS)		Gains/(Losses)			Gains/(Losses)				Loss
	Balance, December 31, 2013		$	(212	)	$	(7	)		$	(219	)
	Other comprehensive income (loss), net of tax		(20		)	2			(a)	(18		)
	Pension plan transfers from Pfizer Inc.(b)		—			(3		)		(3		)
	Balance, September 28, 2014		$	(232	)	$	(8	)		$	(240	)
	(a)	Includes the first quarter 2014 settlement charge associated with the 2012 sale of our Netherlands manufacturing facility. See Note 12. Benefit Plans.
	(b)	Reflects the 2014 transfers of defined benefit pension plans from Pfizer Inc. and the associated reclassification from Additional Paid in Capital to Accumulated other Comprehensive Loss. See Note 12 Benefit Plans.

Financial_Instruments_Tables

Financial Instruments (Tables)	9 Months Ended
	Sep. 28, 2014
Financial Instruments [Abstract]	'
Schedule of Long-term Debt Instruments	'
	The components of our long-term debt follow:
			September 28,			December 31,
	(MILLIONS OF DOLLARS)		2014			2013
	Lines of credit, due 2016-2017		$	2		$	2
	1.150% Senior Notes due 2016		400			400
	1.875% Senior Notes due 2018		750			750
	3.250% Senior Notes due 2023		1,350			1,350
	4.700% Senior Notes due 2043		1,150			1,150
			3,652			3,652
	Unamortized debt discount		(10		)	(10		)
	Long-term debt		$	3,642		$	3,642
Schedule of Maturities of Long-term Debt	'
	The principal amount of long-term debt outstanding as of September 28, 2014, matures in the following years:
															After
	(MILLIONS OF DOLLARS)		2015			2016			2017		2018		2019		2019		Total
	Maturities		$	—		$	401		$	1	$	750	$	—	$	2,500	$	3,652
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	'
	The location and fair values of derivative instruments not designated as hedging instruments are as follows:
			Fair Value of Derivatives
			September 28,			December 31,
	(MILLIONS OF DOLLARS)	Balance Sheet Location	2014			2013
	Foreign currency forward-exchange contracts	Other current assets	$	4		$	10
	Foreign currency forward-exchange contracts	Other current liabilities	(4		)	(5		)
	Total foreign currency forward-exchange contracts		$	—		$	5

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 28, 2014
Inventory Disclosure [Abstract]	'
Components of Inventory	'
	The components of inventory follow:
		September 28,		December 31,
	(MILLIONS OF DOLLARS)	2014		2013
	Finished goods	$	829	$	862
	Work-in-process	277		218
	Raw materials and supplies	282		213
	Inventories	$	1,388	$	1,293

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the Carrying Amount of Goodwill	'
	The components of, and changes in, the carrying amount of goodwill follow:
	(MILLIONS OF DOLLARS)		U.S.		EuAfME			CLAR		APAC		Total
	Balance, December 31, 2013		$	501	$	157		$	162	$	162	$	982
	Other(a)		—		(1		)	—		1		—
	Balance, September 28, 2014		$	501	$	156		$	162	$	163	$	982
	(a)	Primarily reflects adjustments for foreign currency translation.
Components of Identifiable Intangible Assets	'
	The components of identifiable intangible assets follow:
			As of September 28, 2014							As of December 31, 2013
								Identifiable							Identifiable
								Intangible							Intangible
			Gross					Assets, Less		Gross					Assets, Less
			Carrying		Accumulated			Accumulated		Carrying		Accumulated			Accumulated
	(MILLIONS OF DOLLARS)		Amount		Amortization			Amortization		Amount		Amortization			Amortization
	Finite-lived intangible assets:
	Developed technology rights		$	762	$	(253	)	$	509	$	762	$	(219	)	$	543
	Brands		216		(108		)	108		216		(100		)	116
	Trademarks and trade names		60		(40		)	20		59		(38		)	21
	Other		120		(117		)	3		121		(116		)	5
	Total finite-lived intangible assets		1,158		(518		)	640		1,158		(473		)	685
	Indefinite-lived intangible assets:
	Brands		39		—			39		39		—			39
	Trademarks and trade names		67		—			67		67		—			67
	In-process research and development(a)		3		—			3		12		—			12
	Product rights(b)		8		—			8		—		—			—
	Total indefinite-lived intangible assets		117		—			117		118		—			118
	Identifiable intangible assets		$	1,275	$	(518	)	$	757	$	1,276	$	(473	)	$	803
	(a) The in-process research and development (IPR&D) balance as of September 28, 2014, reflects the impairment of IPR&D assets, related to a pharmaceutical product for dogs acquired with the FDAH acquisition in 2009, as a result of the termination of the development program due to a re-assessment of economic viability.
	(b)	Product registration and application rights which were acquired from Pfizer in the third quarter of 2014. See Note 17. Transactions and Agreements with Pfizer.

Sharebased_Payments_Tables

Share-based Payments (Tables)	9 Months Ended
	Sep. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Components of Share-based Compensation Expense	'
	The components of share-based compensation expense follow:
		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,		September 29,
	(MILLIONS OF DOLLARS)	2014		2013		2014		2013
	Stock options / stock appreciation rights	$	5	$	3	$	12	$	7
	RSUs / DSUs	4		3		10		5
	Pfizer stock benefit plans	—		—		—		25
	Share-based compensation expense—total	$	9	$	6	$	22	$	37

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 28, 2014
Earnings Per Share [Abstract]	'
Basic and Diluted Earnings Per Share	'
	The following table presents the calculation of basic and diluted earnings per share:
		Three Months Ended				Nine Months Ended
		September 28,		September 29,		September 28,		September 29,
	(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA)	2014		2013		2014		2013
	Numerator
	Net income before allocation to noncontrolling interests	$	167	$	131	$	461	$	399
	Less: net income attributable to noncontrolling interests	1		—		4		—
	Net income attributable to Zoetis Inc.	$	166	$	131	$	457	$	399
	Denominator
	Weighted-average common shares outstanding	501.453		500		500.887		500
	Common stock equivalents: stock options, RSUs and DSUs	0.992		0.354		0.723		0.227
	Weighted-average common and potential dilutive shares outstanding	502.445		500.354		501.61		500.227
	Earnings per share attributable to Zoetis Inc. stockholders—basic	$	0.33	$	0.26	$	0.91	$	0.8
	Earnings per share attributable to Zoetis Inc. stockholders—diluted	$	0.33	$	0.26	$	0.91	$	0.8

Segment_and_Other_Revenue_Info1

Segment and Other Revenue Information (Tables)	9 Months Ended
	Sep. 28, 2014
Segment Reporting [Abstract]	'
Schedule of Selected Income Statement Information by Segment	'
	Selected Statement of Income Information
													Depreciation and
			Revenue(a)				Earnings(b)						Amortization(c)
			September 28,		September 29,		September 28,			September 29,			September 28,		September 29,
	(MILLIONS OF DOLLARS)		2014		2013		2014			2013			2014		2013
	Three months ended
	U.S.		$	532	$	495	$	313		$	285		$	7	$	11
	EuAfME		293		256		116			90			5		5
	CLAR		194		171		68			56			4		5
	APAC		179		167		71			57			4		4
	Total reportable segments		1,198		1,089		568			488			20		25
	Other business activities(d)		12		14		(75		)	(78		)	7		6
	Reconciling Items:
	Corporate(e)		—		—		(145		)	(139		)	7		4
	Purchase accounting adjustments(f)		—		—		(13		)	(12		)	13		12
	Acquisition-related costs(g)		—		—		(1		)	(1		)	—		—
	Certain significant items(h)		—		—		(38		)	(46		)	1		—
	Other unallocated(i)		—		—		(58		)	(27		)	2		2
			$	1,210	$	1,103	$	238		$	185		$	50	$	49
	Nine months ended
	U.S.		$	1,470	$	1,386	$	849		$	773		$	24	$	33
	EuAfME		847		801		331			297			15		15
	CLAR		576		555		220			186			10		14
	APAC		533		528		209			203			13		10
	Total reportable segments		3,426		3,270		1,609			1,459			62		72
	Other business activities(d)		39		37		(221		)	(225		)	21		21
	Reconciling Items:
	Corporate(e)		—		—		(398		)	(392		)	21		16
	Purchase accounting adjustments(f)		—		—		(38		)	(37		)	38		37
	Acquisition-related costs(g)		—		—		(5		)	(17		)	—		—
	Certain significant items(h)		—		—		(127		)	(130		)	4		—
	Other unallocated(i)		—		—		(155		)	(94		)	5		5
			$	3,465	$	3,307	$	665		$	564		$	151	$	151
	(a)	Revenue denominated in euros was $175 million and $525 million for the three and nine months ended September 28, 2014, respectively, and $159 million and $493 million for the three and nine months ended September 29, 2013, respectively.
	(b)	Defined as income before provision for taxes on income.
	(c)	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
	(d)	Other business activities reflects the research and development costs managed by our Research and Development organization, as well as our contract manufacturing business.
	(e)	Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
	(f)	Purchase accounting adjustments includes certain charges related to intangible assets and property, plant and equipment not charged to our operating segments.
	(g)	Acquisition-related costs can include costs associated with acquiring, integrating and restructuring acquired businesses, such as allocated transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
	(h)	Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain legal and commercial settlements and the impact of divestiture-related gains and losses. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisition and Cost-Reduction/Productivity Initiatives.
	•	In the third quarter of 2014, Certain significant items primarily includes: (i) Zoetis stand-up costs of $32 million; (ii) intangible asset impairment charges related to an IPR&D project acquired with the FDAH acquisition in 2009 of $6 million; and (iii) restructuring charges of $1 million related to employee severance costs in EuAfME. Stand-up costs include certain nonrecurring costs related to becoming an independent public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment costs.
	•	In the third quarter of 2013, Certain significant items primarily includes: (i) Zoetis stand-up costs of $41 million; and (ii) litigation-related charges of $5 million.
	•	In the nine months ended September 28, 2014, Certain significant items primarily includes: (i) Zoetis stand-up costs of $106 million; (ii) charges related to a commercial settlement in Mexico of $13 million, partially offset by the insurance recovery of $1 million income; (iii) restructuring charges of $6 million related to employee severance costs in EuAfME, partially offset by $2 million income related to a reversal of a previously established reserve as a result of a change in estimate of severance costs; (iv) intangible asset impairment charges related to an IPR&D project acquired with the FDAH acquisition in 2009 of $6 million; (v) the Zoetis portion of a net gain on the sale of land by our Taiwan joint venture of $3 million; (vi) additional depreciation associated with asset restructuring of $1 million; (vii) a pension plan settlement charge related to the divestiture of a manufacturing plant of $4 million; and (viii) an insurance recovery of litigation related charges of $2 million income.
	•	In the nine months ended September 29, 2013, Certain significant items primarily includes: (i) Zoetis stand-up costs of $152 million; (ii) $26 million income related to the reversal of certain employee termination expenses; (iii) $6 million income on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009; (iv) additional depreciation associated with asset restructuring of $3 million; and (v) litigation-related charges of $5 million.
	(i)	Includes overhead expenses associated with our manufacturing operations.
Schedule of Significant Product Revenues	'
	Revenue by Species
	Significant species revenue are as follows:
			Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,			September 29,
	(MILLIONS OF DOLLARS)		2014		2013		2014			2013
	Livestock:
	Cattle		$	437	$	387	$	1,207		$	1,132
	Swine		179		154		496			463
	Poultry		147		137		428			412
	Other		27		24		68			65
			790		702		2,199			2,072
	Companion Animal:
	Horses		38		37		127			124
	Dogs and Cats		370		350		1,100			1,074
			408		387		1,227			1,198
	Contract Manufacturing		$	12	$	14	$	39		$	37
	Total revenue		$	1,210	$	1,103	$	3,465		$	3,307
	Revenue by Major Product Category
	Significant revenue by major product category are as follows:
			Three Months Ended				Nine Months Ended
			September 28,		September 29,		September 28,			September 29,
	(MILLIONS OF DOLLARS)		2014		2013		2014			2013
	Anti-infectives		$	356	$	333	$	965		$	920
	Vaccines		308		296		886			867
	Parasiticides		178		156		528			519
	Medicated feed additives		124		94		337			295
	Other pharmaceuticals		200		175		598			555
	Other non-pharmaceuticals		32		35		112			114
	Contract manufacturing		12		14		39			37
	Total revenue		$	1,210	$	1,103	$	3,465		$	3,307

Transactions_and_Agreements_wi1

Transactions and Agreements with Pfizer (Tables)	9 Months Ended
	Sep. 28, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions	'
	The amounts charged under each of the agreements with Pfizer, while Pfizer was still a related party, through the completion of the Exchange Offer on June 24, 2013, were as follows:
	(MILLIONS OF DOLLARS)
	Transitional services agreement	$	63
	Master manufacturing and supply agreements	$	130
	Employee matters agreement	$	99

Organization_Details

Organization (Details)	Sep. 28, 2014
	product_categories
	species
	region
	countries
Product Information [Line Items]	'
Number of regional segments	4
Number of countries in which entity markets products	70
Number of core animal species	8
Number of major product categories	5
Product [Member]	'
Product Information [Line Items]	'
Number of countries in which entity markets products	120

Separation_Activities_and_Init1

Separation Activities and Initial Public Offering (Separation and Senior Notes Offering) (Details) (USD $)	Sep. 28, 2014	Jan. 28, 2013	Jan. 28, 2013	Jan. 28, 2013
		Senior Notes [Member]	Pfizer Transfer [Member]	Pfizer Transfer [Member]
				Senior Notes [Member]
Debt Instrument [Line Items]	'	'	'	'
Senior notes transferred to Pfizer	'	'	'	$1,000,000,000
Cash transferred to Pfizer	'	'	2,500,000,000	'
Debt, principal amount	3,652,000,000	3,650,000,000	'	1,000,000,000
Debt, unamortized discount	'	$10,000,000	'	'

Separation_Activities_and_Init2

Separation Activities and Initial Public Offering (Separation Adjustments) (Details) (Separation Adjustment [Member], USD $)	Dec. 31, 2013
In Millions, unless otherwise specified
Separation Adjustment [Member]	'
Schedule of Separation Adjustments [Line Items]	'
Net liabilities retained by Pfizer	$445

Separation_Activities_and_Init3

Separation Activities and Initial Public Offering (Initial Public Offering) (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Feb. 06, 2013	Feb. 06, 2013	Feb. 06, 2013
			Common Class A [Member]	Common Class B [Member]	IPO [Member]
					Common Class A [Member]
Class of Stock [Line Items]	'	'	'	'	'
Common stock, shares issued	501,209,488	500,007,735	'	'	99,015,000
Share price	'	'	'	'	$26
Common stock, shares outstanding	501,195,696	500,007,428	99,015,000	400,985,000	'
Common Stock, Shares Authorized	6,000,000,000	6,000,000,000	'	'	'
Preferred Stock, Shares Authorized	1,000,000,000	1,000,000,000,000,000	'	'	'

Basis_of_Presentation_Pre_IPO_

Basis of Presentation (Pre IPO Allocations) (Details) (USD $)	3 Months Ended		9 Months Ended		1 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Jan. 28, 2013	Jan. 28, 2013	Jan. 28, 2013
					Allocated Expense From Parent [Member]	Allocated Expense From Parent [Member]	Allocated Expense From Parent [Member]
					Prior to Initial Public Offering [Member]	Prior to Initial Public Offering [Member]	Prior to Initial Public Offering [Member]
						Cost of Sales [Member]	Selling, General and Administrative Expenses [Member]
Schedule of Expenses Allocated from Separation [Line Items]	'	'	'	'	'	'	'
Enabling Functions operating expenses	'	'	'	'	'	'	$11
Additional depreciation associated with asset restructuringbballocated(c)	'	'	'	'	'	'	2
Other costs associated with cost reduction/productivity initiativesbimplementation costs	'	'	'	'	'	'	1
Share-based compensation expense	'	'	'	'	3	1	2
Compensation-related expenses	'	'	'	'	'	'	1
Interest expense, net of capitalized interest	$29	$29	$87	$83	$2	'	'

Restructuring_Charges_and_Othe2

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Dec. 31, 2012

Sep. 28, 2014

Manufacturing, Research, Corporate [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Direct Cost [Member]

Allocated Cost [Member]

Allocated Cost [Member]

Allocated Cost [Member]

Allocated Cost [Member]

Employee Severance [Member]

Employee Severance [Member]

Employee Severance [Member]

Employee Severance [Member]

Employee Severance [Member]

Manufacturing, Research, Corporate [Member]

Cost of Sales [Member]

Selling, General and Administrative Expenses [Member]

United States (U.S.) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Integration costs(a)

'

'

'

'

'

$1

[1]

$3

[1]

$5

[1]

$16

[1]

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges(b):

'

'

-5

'

26

'

'

'

'

1

'

'

'

'

'

'

-4

2

-1

27

-6

Employee termination costs

'

'

'

'

'

1

[2]

0

[2]

4

[2]

-26

[2]

'

'

'

'

'

'

'

'

'

'

'

'

Accelerated depreciation

0

[2]

0

[2]

1

[2]

0

[2]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total Restructuring charges and certain acquisition-related costs

2

3

10

-10

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Additional depreciation associated with asset restructuringbballocated(c)

'

'

'

'

'

0

[3]

0

[3]

0

[3]

1

[3]

'

1

2

0

[3]

0

[3]

0

[3]

2

[3]

'

'

'

'

'

Implementation costsbballocated(d)

'

'

'

'

'

'

'

'

'

'

'

'

0

[4]

0

[4]

0

[4]

1

[4]

'

'

'

'

'

Total costs associated with acquisitions and cost-reduction/productivity initiatives

$2

$3

$10

($6)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Integration costs represent external, incremental costs directly related to integrating acquired businesses and primarily include expenditures for consulting and the integration of systems and processes, as well as product transfer costs.

[2]

The restructuring charges for the three and nine months ended September 28, 2014, include employee severance costs in EuAfME ($1 million and $6 million, respectively). Additionally, the nine months ended September 28, 2014, includes a reversal of a previously established reserve as a result of a change in estimate of severance costs ($2 million benefit), and accelerated depreciation related to the exiting of a research facility ($1 million). The restructuring benefit for the nine months ended September 29, 2013, is primarily related to the reversal of certain employee termination expenses associated with our operations in Europe. The restructuring charges/benefits are associated with the following: b"For the three months ended September 28, 2014bbEuAfME ($1 million). b"For the nine months ended SeptemberB 28, 2014bbEuAfME ($6 million) and Manufacturing/research/corporate ($1 million benefit). b"For the nine months ended SeptemberB 29, 2013bbManufacturing/research/corporate ($26 million benefit).

[3]

Additional depreciation associated with asset restructuring represents the impact of changes in the estimated lives of assets involved in restructuring actions. For the nine months ended September 29, 2013, included in Cost of Sales ($1 million) and Selling, general and administrative expenses ($2 million).

[4]

Implementation costsballocated represent external, incremental costs directly related to implementing cost reduction/productivity initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services. Included in Selling, general and administrative expenses.

Restructuring_Charges_and_Othe3

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Direct restructuring charges) (Details) (USD $)

9 Months Ended

In Millions, unless otherwise specified

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Dec. 31, 2013

Sep. 28, 2014

Dec. 31, 2013

Employee Termination Costs [Member]

Accelerated Depreciation [Member]

Exit Costs [Member]

Other Current Liabilities [Member]

Other Current Liabilities [Member]

Other Noncurrent Liabilities [Member]

Other Noncurrent Liabilities [Member]

Restructuring Cost and Reserve

'

'

'

'

'

'

'

'

Balance, December 31, 2013(a)

$21

[1]

$15

[1]

$0

[1]

$6

[1]

'

'

'

'

Provision

5

4

1

0

'

'

'

'

Utilization and other(b)

-11

[2]

-7

[2]

-1

[2]

-3

[2]

'

'

'

'

Balance, September 28, 2014(a)

15

[1]

12

[1]

0

[1]

3

[1]

'

'

'

'

Restructuring Reserve, Current

'

'

'

'

7

13

'

'

Restructuring Reserve, Noncurrent

'

'

'

'

'

'

$7

$8

[1]

At SeptemberB 28, 2014, and DecemberB 31, 2013, included in Other current liabilities ($7 million and $13 million, respectively) and Other noncurrent liabilities ($7 million and $8 million, respectively)

[2]

Includes adjustments for foreign currency translation.

Other_IncomeDeductions_Net_Det

Other (Income)/Deductions - Net (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013
Other Income and Expenses [Abstract]	'		'		'		'
Royalty-related income	($7)		($8)		($21)		($21)
Identifiable intangible asset impairment charges(a)	6		0		6		1
Gain (Loss) on Disposition of Assets	0	[1]	0	[1]	-6	[1]	-6	[1]
Certain legal and other matters, net(c)	-1	[2]	1	[2]	10	[2]	1	[2]
Foreign currency loss(d)	7	[3]	0	[3]	23	[3]	12	[3]
Other, net(e)	-1	[4]	1	[4]	1	[4]	2	[4]
Nonoperating Income (Expense)	4		-6		13		-11
Litigation Settlement, Expense	'		'		13		'
Insurance Recoveries	$1		'		$2		'
[1]	For the three and nine months ended September 28, 2014, reflects the impairment of IPR&D assets, related to a pharmaceutical product for dogs acquired with the FDAH acquisition in 2009, as a result of the termination of the development program due to a re-assessment of economic viability.
[2]	In July 2014, we reached a commercial settlement with several large poultry customers in Mexico associated with specific lots of a Zoetis poultry vaccine. Although there have been no quality or efficacy issues with the manufacturing of this vaccine, certain shipments from several lots in Mexico may have experienced an issue in storage with a third party in Mexico that could have impacted their efficacy.B We issued a recall of these lots in July 2014 and the product is currently unavailable in Mexico. The nine months ended September 28, 2014, includes a $13 million charge recorded in the second quarter of 2014, which was partially offset by a $1 million insurance recovery recorded in the third quarter of 2014. We do not expect any significant additional charges related to this issue. The nine months ended September 28, 2014, also includes an insurance recovery of other litigation-related charges.
[3]	For the three and nine months ended SeptemberB 28, 2014, primarily driven by costs related to hedging and exposures to certain emerging market currencies. The nine months ended SeptemberB 28, 2014, also includes losses related to the depreciation of the Argentine peso in the first quarter of 2014. For the nine months ended September 29, 2013, primarily related to the Venezuela currency devaluation in February 2013.
[4]	For the nine months ended September 28, 2014, represents the net gain on sale of land in our Taiwan joint venture. For the nine months ended September 29, 2013, represents the net gain on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009.

Income_Taxes_Taxes_on_Income_D

Income Taxes (Taxes on Income) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Effective tax rate for income from continuing operations	29.80%	29.20%	30.70%	29.30%
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	'	'	$8	'
Discrete income tax benefit, research and development tax credit	'	'	'	$2

Income_Taxes_Deferred_Taxes_De

Income Taxes (Deferred Taxes) (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Disclosure [Abstract]	'	'
Net deferred income tax liability	$115	$177
Current deferred tax assets	106	97
Noncurrent deferred tax assets	55	63
Other current deferred liabilities	11	15
Noncurrent deferred tax liabilities	$265	$322

Income_Taxes_Tax_Contingencies

Income Taxes (Tax Contingencies) (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Income Tax Contingency [Line Items]	'	'
Unrecognized tax benefits	$54	$45
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	10	11
Noncurrent Deferred Tax Assets [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Unrecognized tax benefits	7	6
Other Taxes Payable [Member]	'	'
Income Tax Contingency [Line Items]	'	'
Unrecognized tax benefits	$47	$39

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income/(Loss) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014		Sep. 29, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'		'
Balance, December 31, 2013	'	'	($219)		'
Other comprehensive income (loss), net of tax	-39	-62	-18		-82
DefinedPensionPlanTransfer	'	'	0	[1]	'
Balance, September 28, 2014	-240	'	-240		'
Currency Translation Adjustment Net Unrealized Gain/(Losses) [Member]	'	'	'		'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'		'
Balance, December 31, 2013	'	'	-212		'
Other comprehensive income (loss), net of tax	'	'	-20		'
DefinedPensionPlanTransfer	'	'	'	[2]	'
Balance, September 28, 2014	-232	'	-232		'
Benefit Plans Actuarial Gains/(Losses) [Member]	'	'	'		'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'		'
Balance, December 31, 2013	'	'	-7		'
Other comprehensive income (loss), net of tax	'	'	2	[3]	'
DefinedPensionPlanTransfer	'	'	-3	[2]	'
Balance, September 28, 2014	-8	'	-8		'
Accumulated Other Comp. Income/(Loss)	'	'	'		'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'		'
Balance, December 31, 2013	'	'	-219		'
Other comprehensive income (loss), net of tax	'	'	-18		-82
DefinedPensionPlanTransfer	'	'	-3	[1],[2]	'
Balance, September 28, 2014	($240)	'	($240)		'
[1]	Reflects the 2014 transfers of defined benefit pension plans from Pfizer Inc. and the associated reclassification from Additional Paid in Capital to Accumulated Other Comprehensive Loss. See Note 12. Benefit Plans.
[2]	Reflects the 2014 transfers of defined benefit pension plans from Pfizer Inc. and the associated reclassification from Additional Paid in Capital to Accumulated other Comprehensive Loss. See Note 12 Benefit Plans.
[3]	Includes the first quarter 2014 settlement charge associated with the 2012 sale of our Netherlands manufacturing facility. See Note 12. Benefit Plans.

Financial_Instruments_Credit_F

Financial Instruments (Credit Facility) (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2012
				Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]	'	'	'	'
Revolving credit facility, term	'	'	'	'5 years
Revolving credit facility, current borrowing capacity	'	'	'	$1,000,000,000
Revolving credit facility, covenant compliance ratio, 2014	'	'	'	3.95
Revolving credit facility, covenant compliance ratio, 2015	'	'	'	3.5
Revolving credit facility, covenant compliance ratio, 2016 and thereafter	'	'	'	3
Line of credit facility, maximum borrowing capacity	73,000,000	'	'	1,500,000,000
Line of Credit Facility, Amount Outstanding	0	0	'	'
Short-term Bank Loans and Notes Payable	10,000,000	15,000,000	'	'
Long-term Line of Credit	$2,000,000	$2,000,000	'	'
Revolving credit facility, minimum interest coverage ratio	'	'	3.5	'

Financial_Instruments_Commerci

Financial Instruments (Commercial Paper) (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Feb. 28, 2013
			Commercial Paper [Member]
Short-term Debt [Line Items]	'	'	'
Capacity of commercial paper program	'	'	$1,000,000,000
Commercial Paper	$0	$0	'

Financial_Instruments_ShortTer

Financial Instruments (Short-Term Borrowings) (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Financial Instruments [Abstract]	'	'
Short-term Bank Loans and Notes Payable	$10	$15
Short-term debt, weighted-average effective interest rate	8.00%	5.70%

Financial_Instruments_Senior_N

Financial Instruments (Senior Notes Offering) (Details) (USD $)	Sep. 28, 2014	Jan. 28, 2013
In Millions, unless otherwise specified
Debt Instrument [Line Items]	'	'
Debt, principal amount	$3,652	'
Senior Notes [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	'	3,650
Debt, unamortized discount	'	10
Debt, purchase price percent due to downgrade of investment grade	'	101.00%
Senior Notes [Member] | Initial Purchasers [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	'	2,650
Senior Notes [Member] | Pfizer Transfer [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	'	1,000
Senior Notes [Member] | Senior Notes 1.150% due 2016 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	400	400
Debt, stated interest rate	'	1.15%
Senior Notes [Member] | Senior Notes 1.875% due 2018 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	750	750
Debt, stated interest rate	'	1.88%
Senior Notes [Member] | Senior Notes 3.250% due 2023 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	1,350	1,350
Debt, stated interest rate	'	3.25%
Senior Notes [Member] | Senior Notes 4.700% due 2043 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt, principal amount	$1,150	$1,150
Debt, stated interest rate	'	4.70%

Financial_Instruments_Schedule

Financial Instruments (Schedule of Long-term Debt) (Details) (USD $)

Sep. 28, 2014

Dec. 31, 2013

Jan. 28, 2013

Sep. 28, 2014

Jan. 28, 2013

Sep. 28, 2014

Jan. 28, 2013

Sep. 28, 2014

Jan. 28, 2013

Sep. 28, 2014

Jan. 28, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

In Millions, unless otherwise specified

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Prior to Initial Public Offering [Member]

Senior Notes 1.150% due 2016 [Member]

Senior Notes 1.150% due 2016 [Member]

Senior Notes 1.875% due 2018 [Member]

Senior Notes 1.875% due 2018 [Member]

Senior Notes 3.250% due 2023 [Member]

Senior Notes 3.250% due 2023 [Member]

Senior Notes 4.700% due 2043 [Member]

Senior Notes 4.700% due 2043 [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes [Member]

Senior Notes 1.150% due 2016 [Member]

Senior Notes 1.875% due 2018 [Member]

Senior Notes 3.250% due 2023 [Member]

Senior Notes 4.700% due 2043 [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Line of Credit, Noncurrent

$2

$2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total long-term debt

3,652

'

3,650

400

400

750

750

1,350

1,350

1,150

1,150

3,652

400

750

1,350

1,150

Unamortized debt discount

-10

'

'

'

'

'

'

'

'

'

'

-10

'

'

'

'

Long-term debt

$3,642

$3,642

'

'

'

'

'

'

'

'

'

$3,642

'

'

'

'

Financial_Instruments_Fair_Val

Financial Instruments (Fair Value of Debt) (Details) (Fair Value, Inputs, Level 2 [Member], USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Senior Notes [Member]	Allocated Long-term Debt [Member]
Debt Instrument [Line Items]	'	'
Fair value, debt instrument	$3,648	$3,526

Financial_Instruments_Longterm

Financial Instruments (Long-term Debt Maturity) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Financial Instruments [Abstract]	'	'	'	'
2014	$0	'	$0	'
2015	401	'	401	'
2016	1	'	1	'
2017	750	'	750	'
2018	0	'	0	'
After 2018	2,500	'	2,500	'
Total long-term debt	3,652	'	3,652	'
Interest expense, net of capitalized interest	29	29	87	83
Interest Costs Capitalized	$1	$1	$3	$2

Financial_Instruments_Foreign_

Financial Instruments Foreign Exchange Risk (Details) (Foreign Exchange Contract [Member], USD $)	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Sep. 28, 2014
In Billions, unless otherwise specified			Majority [Member]	Maximum [Member]
Derivative [Line Items]	'	'	'	'
Derivative, Notional Amount	$1.10	$1.40	'	'
Derivative, Term of Contract	'	'	'60 days	'180 days

Financial_Instruments_Fair_Val1

Financial Instruments (Fair Value of Derivative Instruments) (Details) (Foreign Exchange Forward [Member], USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Dec. 31, 2013
					Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]	Not Designated as Hedging Instrument [Member]
							Other Current Assets [Member]	Other Current Assets [Member]	Other Current Liabilities [Member]	Other Current Liabilities [Member]
Derivatives, Fair Value [Line Items]	'	'	'	'	'	'	'	'	'	'
Foreign currency forward-exchange contracts	'	'	'	'	'	'	$4	$10	'	'
Foreign currency forward-exchange contracts	'	'	'	'	'	'	'	'	-4	-5
Total foreign currency forward-exchange contracts	'	'	'	'	0	5	'	'	'	'
Gain (loss) on derivative contracts not designated as hedging instruments	$1	$13	$1	$32	'	'	'	'	'	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Finished goods	$829	$862
Work-in-process	277	218
Raw materials and supplies	282	213
Inventories	$1,388	$1,293

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets (Goodwill) (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014
Goodwill [Roll Forward]	'
Balance, December 31, 2013	$982
Other(a)	0
Balance, September 28, 2014	982
United States (U.S.) [Member]	'
Goodwill [Roll Forward]	'
Balance, December 31, 2013	501
Other(a)	0	[1]
Balance, September 28, 2014	501
Europe, Africa, and Middle East (EuAfME) [Member]	'
Goodwill [Roll Forward]	'
Balance, December 31, 2013	157
Other(a)	-1	[1]
Balance, September 28, 2014	156
Canada and Latin America (CLAR) [Member]	'
Goodwill [Roll Forward]	'
Balance, December 31, 2013	162
Other(a)	0	[1]
Balance, September 28, 2014	162
Asia Pacific (APAC) [Member]	'
Goodwill [Roll Forward]	'
Balance, December 31, 2013	162
Other(a)	1	[1]
Balance, September 28, 2014	$163
[1]	Primarily reflects adjustments for foreign currency translation.

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets (Finite-lived and Indefinite-lived Intangible Assets) (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, Gross Carrying Amount	$1,158	$1,158
Finite-lived intangible assets, Accumulated Amortization	-518	-473
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	640	685
Total indefinite-lived intangible assets	117	118
Intangible Assets, Gross Carrying Amount	1,275	1,276
Identifiable Intangible Assets, Less Accumulated Amortization	757	803
Brands [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Total indefinite-lived intangible assets	39	39
Trademarks and Trade Names [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Total indefinite-lived intangible assets	67	67
In Process Research And Development [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Total indefinite-lived intangible assets	3	12
ProductRights [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Total indefinite-lived intangible assets	8	'
Developed Technology Rights [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, Gross Carrying Amount	762	762
Finite-lived intangible assets, Accumulated Amortization	-253	-219
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	509	543
Brands [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, Gross Carrying Amount	216	216
Finite-lived intangible assets, Accumulated Amortization	-108	-100
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	108	116
Trademarks and Trade Names [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, Gross Carrying Amount	60	59
Finite-lived intangible assets, Accumulated Amortization	-40	-38
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	20	21
Other Intangible Assets [Member]	'	'
Finite Lived and Indefinite Lived Intangible Assets [Line Items]	'	'
Finite-lived intangible assets, Gross Carrying Amount	120	121
Finite-lived intangible assets, Accumulated Amortization	-117	-116
Finite-lived intangible assets, Identifiable Intangible Assets, Less Accumulated Amortization	$3	$5

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'	'
Gross goodwill	$1,518	'	$1,518	'	$1,518
Accumulated goodwill impairment losses	536	'	536	'	536
Amortization expense for finite-lived intangible assets	$15	$16	$47	$47	'

Benefit_Plans_Details

Benefit Plans (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Dec. 31, 2012

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Dec. 31, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Dec. 31, 2012

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

U.S. Plan [Member]

U.S. Plan [Member]

U.S. Plan [Member]

U.S. Plan [Member]

U.S. Plan [Member]

International Pension Plans [Member]

International Pension Plans [Member]

International Pension Plans [Member]

International Pension Plans [Member]

International Pension Plans in Other Locations [Member]

International Pension Plans in Other Locations [Member]

Multi-employer Plan [Member]

Multi-employer Plan [Member]

Multi-employer Plan [Member]

Multi-employer Plan [Member]

Pfizer [Member]

JAPAN

SWITZERLAND

NETHERLANDS

U.S. Plan [Member]

Pfizer [Member]

Pfizer [Member]

Supplemental Saving Plan [Member]

Supplemental Saving Plan [Member]

Defined Benefit Plan Disclosure [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of total cost of the service credit continuation Zoetis will be responsible for

'

'

'

'

'

'

'

'

60.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of total cost of the service credit continuation Pfizer will be responsible for

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

40.00%

'

'

'

Pension and postretirement benefit expense

'

'

'

'

$2

$1

$5

$5

'

$2

$1

$9

$3

'

'

$1

$2

$4

$7

'

'

'

'

Supplemental savings plan liability transferred from Pfizer

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-2

-1

'

Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2

1

'

Estimated net obligation

'

'

'

'

'

'

'

'

'

'

'

'

'

18

21

'

'

'

'

'

'

'

'

Contributions to benefit plans

2

2

6

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected future contributions to benefit plans

'

'

8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Other Comprehensive Income Pension Plan Settlement Charge Before Tax

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4

Plan settlement, net(b)

$0

[1]

$0

[1]

$3

[1]

$0

[1]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3

[1]

Reflects the first quarter 2014 settlement charge associated with the 2012 sale of our Netherlands manufacturing facility which was recorded to Other (income)/deductionsbnet. See Note 12. Benefit Plans for additional information.

Sharebased_Payments_Narrative_

Share-based Payments (Narrative) (Details) (USD $)	9 Months Ended
	Sep. 28, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,006,351
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$30.97
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$8.01
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.01%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.93%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	24.70%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	'6 years 6 months
Restricted Stock Units (RSUs) [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Granted (in shares)	837,990
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$30.99
Award vesting period	'3 years
Deferred Stock Units (DSUs) [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Granted (in shares)	36,256
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$30.89

Sharebased_Payments_Components

Share-based Payments (Components of share-based compensation expense) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebtotal	$9	$6	$22	$37
Stock Options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebdirect	5	3	12	7
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebdirect	4	3	10	5
Pfizer Stock Benefit Plans [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based compensation expensebdirect	$0	$0	$0	$25

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	'	'	3,000,000	2,000,000
Numerator	'	'	'	'
Net income before allocation to noncontrolling interests	$167	$131	$461	$399
Less: net income attributable to noncontrolling interests	1	0	4	0
Net income attributable to Zoetis Inc.	$166	$131	$457	$399
Denominator	'	'	'	'
Weighted-average common shares outstanding	501,453,000	500,000,000	500,887,000	500,000,000
Common stock equivalents: stock options, RSUs and DSUs	992,000	354,000	723,000	227,000
Weighted-average common and potential dilutive shares outstanding	502,445,000	500,354,000	501,610,000	500,227,000
Earnings per share attributable to Zoetis stockholdersbbasic (in dollars per share)	$0.33	$0.26	$0.91	$0.80
Earnings per share attributable to Zoetis stockholdersbdiluted (in dollars per share)	$0.33	$0.26	$0.91	$0.80

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	3 Months Ended	9 Months Ended			9 Months Ended		0 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 28, 2014	Sep. 29, 2013	Sep. 29, 2013	Sep. 28, 2014	Sep. 28, 2014	Aug. 13, 2013	Feb. 29, 2012	Sep. 28, 2014
	USD ($)	USD ($)	USD ($)	EUR (€)	Roxarsone (3-Nitro) [Member]	PregSure [Member]	Ulianopolis, Brazil [Member]	Ulianopolis, Brazil [Member]	Mary Green [Member]
					plaintiffs	claims	plaintiffs	defendant	Roxarsone (3-Nitro) [Member]
					claims		defendant		claims
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'
Number of claims seeking damages	'	'	'	'	9	240	'	6	1
Number of plaintiffs	'	'	'	'	140	'	30	'	'
Number of claims settled	'	'	'	'	'	128	'	'	'
Number of additional defendants	'	'	'	'	'	'	57	5	'
Loss Contingency Accrual, Period Increase (Decrease)	'	'	$14	€ 11	'	'	'	'	'
Litigation Settlement, Expense	'	13	'	'	'	'	'	'	'
Insurance Recoveries	$1	$2	'	'	'	'	'	'	'

Segment_and_Other_Revenue_Info2

Segment and Other Revenue Information Segment Information (Details) (USD $)

9 Months Ended

3 Months Ended

In Millions, unless otherwise specified

Sep. 28, 2014

Dec. 31, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

segment

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Income Before Taxes [Member]

Income Before Taxes [Member]

Income Before Taxes [Member]

Income Before Taxes [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Contract Manufacturing [Member]

Companion Animal [Member]

Companion Animal [Member]

Companion Animal [Member]

Companion Animal [Member]

Livestock [Member]

Livestock [Member]

Livestock [Member]

Livestock [Member]

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Prior Period Reclassification Adjustment

'

$16

$14

$12

$11

$11

$10

$9

$8

$5

$4

$3

$3

$5

$2

($2)

$3

Number of Operating Segments

4

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Segment_and_Other_Revenue_Info3

Segment and Other Revenue Information Segment Assets (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Millions, unless otherwise specified
Segment Reporting [Abstract]	'	'
Assets	$6,527	$6,558

Segment_and_Other_Revenue_Info4

Segment and Other Revenue Information (Income Statement) (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	$1,210	[1]	$1,103	[1]	$3,465	[1]	$3,307	[1]
Earnings	238	[2]	185	[2]	665	[2]	564	[2]
Depreciation and Amortization	50	[3]	49	[3]	151	[3]	151	[3]
Reportable Segment [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	1,198	[1]	1,089	[1]	3,426	[1]	3,270	[1]
Earnings	568	[2]	488	[2]	1,609	[2]	1,459	[2]
Depreciation and Amortization	20	[3]	25	[3]	62	[3]	72	[3]
Other business activities [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	12	[1],[4]	14	[1],[4]	39	[1],[4]	37	[1],[4]
Earnings	-75	[2],[4]	-78	[2],[4]	-221	[2],[4]	-225	[2],[4]
Depreciation and Amortization	7	[3],[4]	6	[3],[4]	21	[3],[4]	21	[3],[4]
Corporate [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	'		'		0	[1],[5]	0	[1],[5]
Earnings	-145	[2],[5]	-139	[2],[5]	-398	[2],[5]	-392	[2],[5]
Depreciation and Amortization	7	[3],[5]	4	[3],[5]	21	[3],[5]	16	[3],[5]
Purchase accounting adjustments [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	'		'		0	[1],[6]	0	[1],[6]
Earnings	-13	[2],[6]	-12	[2],[6]	-38	[2],[6]	-37	[2],[6]
Depreciation and Amortization	13	[3],[6]	12	[3],[6]	38	[3],[6]	37	[3],[6]
Acquisition-related costs [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	'		'		0	[1],[7]	0	[1],[7]
Earnings	-1	[2],[7]	-1	[2],[7]	-5	[2],[7]	-17	[2],[7]
Depreciation and Amortization	0	[3],[7]	0	[3],[7]	0	[3],[7]	0	[3],[7]
Certain Significant Items [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	'		'		0	[1],[8]	0	[1],[8]
Earnings	-38	[2],[8]	-46	[2],[8]	-127	[2],[8]	-130	[2],[8]
Depreciation and Amortization	1	[3],[8]	0	[3],[8]	4	[3],[8]	0	[3],[8]
Other unallocated [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	'		'		0	[1],[9]	0	[1],[9]
Earnings	-58	[2],[9]	-27	[2],[9]	-155	[2],[9]	-94	[2],[9]
Depreciation and Amortization	2	[3],[9]	2	[3],[9]	5	[3],[9]	5	[3],[9]
United States (U.S.) [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	532	[1]	495	[1]	1,470	[1]	1,386	[1]
Earnings	313	[2]	285	[2]	849	[2]	773	[2]
Depreciation and Amortization	7	[3]	11	[3]	24	[3]	33	[3]
Europe, Africa, and Middle East (EuAfME) [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	293	[1]	256	[1]	847	[1]	801	[1]
Earnings	116	[2]	90	[2]	331	[2]	297	[2]
Depreciation and Amortization	5	[3]	5	[3]	15	[3]	15	[3]
Canada and Latin America (CLAR) [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	194	[1]	171	[1]	576	[1]	555	[1]
Earnings	68	[2]	56	[2]	220	[2]	186	[2]
Depreciation and Amortization	4	[3]	5	[3]	10	[3]	14	[3]
Asia Pacific (APAC) [Member]	'		'		'		'
Segment Reporting Information [Line Items]	'		'		'		'
Revenue	179	[1]	167	[1]	533	[1]	528	[1]
Earnings	71	[2]	57	[2]	209	[2]	203	[2]
Depreciation and Amortization	$4	[3]	$4	[3]	$13	[3]	$10	[3]
[1]	Revenue denominated in euros was $175 million and $525 million for the three and nine months ended SeptemberB 28, 2014, respectively, and $159 million and $493 million for the three and nine months ended SeptemberB 29, 2013, respectively.
[2]	Defined as income before provision for taxes on income.
[3]	Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
[4]	Other business activities reflects the research and development costs managed by our Research and Development organization, as well as our contract manufacturing business.
[5]	Corporate includes, among other things, administration expenses, interest expense, certain compensation and other costs not charged to our operating segments.
[6]	Purchase accounting adjustments includes certain charges related to intangible assets and property, plant and equipment not charged to our operating segments.
[7]	Acquisition-related costs can include costs associated with acquiring, integrating and restructuring acquired businesses, such as allocated transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 5. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.
[8]	Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain legal and commercial settlements and the impact of divestiture-related gains and losses. For additional information, see NoteB 5. Restructuring Charges and Other Costs Associated with Acquisition and Cost-Reduction/Productivity Initiatives. b"In the third quarter of 2014, Certain significant items primarily includes: (i) Zoetis stand-up costs of $32 million; (ii) intangible asset impairment charges related to an IPR&D project acquired with the FDAH acquisition in 2009 of $6 million; and (iii) restructuring charges of $1 million related to employee severance costs in EuAfME. Stand-up costs include certain nonrecurring costs related to becoming an independent public company, such as new branding (including changes to the manufacturing process for required new packaging), the creation of standalone systems and infrastructure, site separation, and certain legal registration and patent assignment costs.b"In the third quarter of 2013, Certain significant items primarily includes: (i) Zoetis stand-up costs of $41 million; and (ii) litigation-related charges of $5 million. b"In the nine months ended September 28, 2014, Certain significant items primarily includes: (i) Zoetis stand-up costs of $106 million; (ii) charges related to a commercial settlement in Mexico of $13 million, partially offset by the insurance recovery of $1 million income; (iii) restructuring charges of $6 million related to employee severance costs in EuAfME, partially offset by $2 million income related to a reversal of a previously established reserve as a result of a change in estimate of severance costs; (iv) intangible asset impairment charges related to an IPR&D project acquired with the FDAH acquisition in 2009 of $6 million; (v) the Zoetis portion of a net gain on the sale of land by our Taiwan joint venture of $3 million; (vi) additional depreciation associated with asset restructuring of $1 million; (vii) a pension plan settlement charge related to the divestiture of a manufacturing plant of $4 million; and (viii) an insurance recovery of litigation related charges of $2 million income. b"In the nine months ended September 29, 2013, Certain significant items primarily includes: (i) Zoetis stand-up costs of $152 million; (ii) $26 million income related to the reversal of certain employee termination expenses; (iii) $6 million income on the government-mandated sale of certain product rights in Brazil that were acquired with the FDAH acquisition in 2009; (iv) additional depreciation associated with asset restructuring of $3 million; and (v) litigation-related charges of $5 million.
[9]	Includes overhead expenses associated with our manufacturing operations

Segment_and_Other_Revenue_Info5

Segment and Other Revenue Information (Income Statement Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Dec. 31, 2012

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Certain Significant Items [Member]

Certain Significant Items [Member]

Certain Significant Items [Member]

Certain Significant Items [Member]

Euro Member Countries, Euro

Euro Member Countries, Euro

Euro Member Countries, Euro

Euro Member Countries, Euro

Employee Severance [Member]

Employee Severance [Member]

Employee Severance [Member]

Employee Severance [Member]

Employee Severance [Member]

MEXICO

NETHERLANDS

In Process Research And Development [Member]

In Process Research And Development [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

Europe, Africa, and Middle East (EuAfME) [Member]

UNITED STATES

Certain Significant Items [Member]

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenues denominated in Euros

'

'

'

'

'

'

'

'

$175

$159

$525

$493

'

'

'

'

'

'

'

'

'

Stand-up costs

'

'

'

'

32

41

106

152

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6

6

Restructuring charges

'

'

-5

'

'

'

'

26

'

'

'

'

-4

-1

27

-6

2

'

'

'

'

Gain (Loss) Related to Litigation Settlement

'

'

'

'

'

5

'

5

'

'

'

'

'

'

'

'

'

13

'

'

'

Insurance Recoveries

1

'

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

Gain (Loss) on Disposition of Assets

0

[1]

0

[1]

6

[1]

6

[1]

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accelerated depreciation

0

[2]

0

[2]

1

[2]

0

[2]

'

'

'

3

'

'

'

'

'

'

'

'

'

'

'

'

'

Dedicated Pension Plans, Settlement Charge for Contract Termination

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4

'

'

[1]

For the three and nine months ended September 28, 2014, reflects the impairment of IPR&D assets, related to a pharmaceutical product for dogs acquired with the FDAH acquisition in 2009, as a result of the termination of the development program due to a re-assessment of economic viability.

[2]

The restructuring charges for the three and nine months ended September 28, 2014, include employee severance costs in EuAfME ($1 million and $6 million, respectively). Additionally, the nine months ended September 28, 2014, includes a reversal of a previously established reserve as a result of a change in estimate of severance costs ($2 million benefit), and accelerated depreciation related to the exiting of a research facility ($1 million). The restructuring benefit for the nine months ended September 29, 2013, is primarily related to the reversal of certain employee termination expenses associated with our operations in Europe. The restructuring charges/benefits are associated with the following: b"For the three months ended September 28, 2014bbEuAfME ($1 million). b"For the nine months ended SeptemberB 28, 2014bbEuAfME ($6 million) and Manufacturing/research/corporate ($1 million benefit). b"For the nine months ended SeptemberB 29, 2013bbManufacturing/research/corporate ($26 million benefit).

Segment_and_Other_Revenue_Info6

Segment and Other Revenue Information (Revenue by Animal Species) (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$1,210	[1]	$1,103	[1]	$3,465	[1]	$3,307	[1]
Livestock [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	790		702		2,199		2,072
Cattle [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	437		387		1,207		1,132
Swine [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	179		154		496		463
Poultry [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	147		137		428		412
Other (Fish and Sheep) [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	27		24		68		65
Companion Animal [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	408		387		1,227		1,198
Horses [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	38		37		127		124
Dogs and Cats [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	370		350		1,100		1,074
Other Non Pharmaceuticals [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	32		35		112		114
Contract Manufacturing [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$12		$14		$39		$37
[1]	Revenue denominated in euros was $175 million and $525 million for the three and nine months ended SeptemberB 28, 2014, respectively, and $159 million and $493 million for the three and nine months ended SeptemberB 29, 2013, respectively.

Segment_and_Other_Revenue_Info7

Segment and Other Revenue Information (Revenue by Product) (Details) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$1,210	[1]	$1,103	[1]	$3,465	[1]	$3,307	[1]
Anti-infectives [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	356		333		965		920
Vaccines [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	308		296		886		867
Parasiticides [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	178		156		528		519
Medicated feed additives [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	124		94		337		295
Other pharmaceuticals [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	200		175		598		555
Other Non Pharmaceuticals [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	32		35		112		114
Contract Manufacturing [Member]	'		'		'		'
Revenue from External Customer [Line Items]	'		'		'		'
Revenue	$12		$14		$39		$37
[1]	Revenue denominated in euros was $175 million and $525 million for the three and nine months ended SeptemberB 28, 2014, respectively, and $159 million and $493 million for the three and nine months ended SeptemberB 29, 2013, respectively.

Transactions_and_Agreements_wi2

Transactions and Agreements with Pfizer (Agreements with Pfizer) (Details) (USD $)	3 Months Ended							3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Sep. 28, 2014	Sep. 28, 2014	Sep. 28, 2014	Sep. 28, 2014
		manufacturing_site		Pfizer [Member]	Pfizer [Member]	Anchor Manufacturing Sites [Member]	Satellite Manufacturing Sites [Member]	Other Current Liabilities [Member]	Other Noncurrent Liabilities [Member]	ProductRights [Member]
				manufacturing_site		manufacturing_site	manufacturing_site
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'
Number of manufacturing facilities	'	27	'	'	'	13	14	'	'	'
Number of manufacturing facilities retained by Pfizer	'	'	'	13	'	'	'	'	'	'
Indefinite-Lived Intangible Assets (Excluding Goodwill)	'	$117	$118	'	'	'	'	'	'	$8
Payments to Acquire Intangible Assets	2	'	'	'	'	'	'	'	'	'
Noncash or Part Noncash Acquisition, Payables Assumed	'	'	'	'	'	'	'	2	6	'
Accounts receivable	'	1,057	1,138	36	121	'	'	'	'	'
Accounts payable	'	$259	$506	$63	$181	'	'	'	'	'

Transactions_and_Agreements_wi3

Transactions and Agreements with Pfizer (Post-Separation Agreements with Pfizer) (Details) (Pfizer [Member], USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013
Transitional Services Agreement [Member]	'
Related Party Transaction [Line Items]	'
Amount charged under agreement with Pfizer	$63
Master Manufacturing and Supply Agreements [Member]	'
Related Party Transaction [Line Items]	'
Amount charged under agreement with Pfizer	130
Employee Matters Agreement [Member]	'
Related Party Transaction [Line Items]	'
Amount charged under agreement with Pfizer	$99